cached image

Mark A. Wainberg - Publications

Affiliations: 
McGill University, Montreal, QC, Canada 
Area:
Microbiology Biology
Website:
https://www.miamiherald.com/news/local/community/gay-south-florida/article144222904.html

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Raffi F, Wainberg MA. Antiretroviral therapy with integrase inhibitors: more options. Virologie (Montrouge, France). 17: 54-60. PMID 31910534 DOI: 10.1684/vir.2013.0479  0.346
2018 Van Rompay KK, Hassounah S, Keele BF, Lifson JD, Ardeshir A, Watanabe J, Pham HT, Chertova E, Sowder R, Balzarini J, Mesplède T, Wainberg MA. Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes. Journal of Virology. PMID 30381490 DOI: 10.1128/Jvi.01189-18  0.578
2018 Anstett K, Brenner B, Mesplède T, Wainberg MA. Correction for Anstett et al., "HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity". Journal of Virology. 92. PMID 30258035 DOI: 10.1128/Jvi.01156-18  0.432
2018 Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA. Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration". Mbio. 9. PMID 30254122 DOI: 10.1128/Mbio.01450-18  0.414
2018 Osman N, Mesplède T, Oliveira M, Hassounah S, Wainberg MA, Brenner BG. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout. Aids (London, England). PMID 29894388 DOI: 10.1097/Qad.0000000000001903  0.623
2018 Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg MA, Makhema J, Marlink R, Novitsky V, Essex M. Prevalence of Rilpivirine and Etravirine resistance mutations in HIV-1 Subtype C- infected patients failing Nevirapine or Efavirenz-based combination antiretroviral therapy in Botswana. Aids Research and Human Retroviruses. PMID 29732907 DOI: 10.1089/Aid.2017.0135  0.583
2018 Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, Goring M, Han Y, Lungu C, van der Ende ME, Brenner BG, Boucher CA, Rijnders BJA, van Kampen JJA, Mesplède T, ... Wainberg MA, et al. The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance. The Journal of Infectious Diseases. PMID 29617824 DOI: 10.1093/Infdis/Jiy175  0.504
2018 Tietjen I, Williams DE, Read S, Kuang XT, Mwimanzi P, Wilhelm E, Markle T, Kinloch NN, Naphen CN, Tenney K, Mesplède T, Wainberg MA, Crews P, Bell B, Andersen RJ, et al. Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A. Antiviral Research. PMID 29476895 DOI: 10.1016/J.Antiviral.2018.02.017  0.566
2018 Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. Journal of Medical Virology. PMID 29315671 DOI: 10.1002/Jmv.25031  0.378
2018 Ge Y, Zhou B, Xiao R, Yuan X, Zhou H, Xu Y, Wainberg MA, Han Y, Yue J. A new class of HIV-1 inhibitors and the target identification via proteomic profiling Science China Chemistry. 61: 1430-1439. DOI: 10.1007/S11426-018-9283-3  0.501
2017 Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, Fafi-Kremer S. Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. The Journal of Antimicrobial Chemotherapy. PMID 29244129 DOI: 10.1093/Jac/Dkx475  0.513
2017 Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, ... ... Wainberg MA, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. The Lancet. Hiv. PMID 29174084 DOI: 10.1016/S2352-3018(17)30190-X  0.328
2017 Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill MJ, Haddad E, Guimond JV, Wainberg MA, Baker GB, Cohen EA, Power C. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. Retrovirology. 14: 47. PMID 29037245 DOI: 10.1186/S12977-017-0370-5  0.519
2017 Godfrey C, Thigpen MC, Crawford KW, Jean-Phillippe P, Pillay D, Persaud D, Kuritzkes DR, Wainberg M, Raizes E, Fitzgibbon J. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. The Journal of Infectious Diseases. PMID 28973412 DOI: 10.1093/Infdis/Jix137  0.515
2017 Oliveira M, Brenner BG, Xu H, Ibanescu RI, Mesplède T, Wainberg MA. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. The Journal of Antimicrobial Chemotherapy. PMID 28961903 DOI: 10.1093/Jac/Dkx280  0.462
2017 Han Y, Mesplède T, Wainberg MA. Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion On Investigational Drugs. 1-7. PMID 28956664 DOI: 10.1080/13543784.2017.1378643  0.348
2017 Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, Xu HT, Brenner BG, Mesplède T, Wainberg MA. Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1. Antimicrobial Agents and Chemotherapy. PMID 28923862 DOI: 10.1128/AAC.01695-17  0.509
2017 Anstett K, Brenner B, Mesplède T, Wainberg MA. HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity. Journal of Virology. PMID 28835492 DOI: 10.1128/JVI.00912-17  0.512
2017 Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA. Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication(). Scientific Reports. 7: 6345. PMID 28740124 DOI: 10.1038/S41598-017-06612-2  0.375
2017 Heredia A, Hassounah S, Medina-Moreno S, Zapata JC, Le NM, Han Y, Foulke JS, Davis C, Bryant J, Redfield RR, Wainberg MA. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice. The Journal of Antimicrobial Chemotherapy. PMID 28637235 DOI: 10.1093/jac/dkx195  0.41
2017 Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 14: 36. PMID 28583191 DOI: 10.1186/S12977-017-0360-7  0.545
2017 Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quiñones-Mateu ME, Wainberg MA. HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. The Journal of Antimicrobial Chemotherapy. PMID 28472323 DOI: 10.1093/Jac/Dkx118  0.393
2017 Melnychuk L, Ajamian L, Jean-Pierre P, Liang J, Gheorghe R, Wainberg MA, Zaharatos GJ. Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region. Vaccine. PMID 28392143 DOI: 10.1016/J.Vaccine.2017.03.039  0.378
2017 Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. Mbio. 8. PMID 28377526 DOI: 10.1128/Mbio.00157-17  0.572
2017 Quan Y, Xu H, Han Y, Mesplède T, Wainberg MA. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope Mutated HIV-1. Journal of Virology. PMID 28202754 DOI: 10.1128/Jvi.00075-17  0.532
2017 Palanisamy N, Osman N, Ohnona F, Xu HT, Brenner B, Mesplède T, Wainberg MA. Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. Aids Research and Therapy. 14: 2. PMID 28086981 DOI: 10.1186/S12981-016-0130-Y  0.576
2017 Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. The Journal of Antimicrobial Chemotherapy. PMID 28069884 DOI: 10.1093/Jac/Dkw514  0.351
2017 Wainberg M. I-103 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness Journal of Acquired Immune Deficiency Syndromes. 74: 66. DOI: 10.1097/01.Qai.0000513875.61517.23  0.391
2016 Hassounah SA, Mesplède T, Wainberg MA. Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review. Pathogens & Immunity. 1: 41-67. PMID 30993244 DOI: 10.20411/pai.v1i1.104  0.49
2016 Brenner BG, Ibanescu RI, Hardy I, Stephens D, Otis J, Moodie E, Grossman Z, Vandamme AM, Roger M, Wainberg MA. Large cluster outbreaks sustain the HIV epidemic among men having sex with men (MSM) in Quebec from 2002 to 2015. Aids (London, England). PMID 28005684 DOI: 10.1097/Qad.0000000000001383  0.469
2016 Wainberg MA, Lever AM. HIV and Zika: When will we be able to end these epidemics? Retrovirology. 13: 80. PMID 27846847 DOI: 10.1186/S12977-016-0315-4  0.497
2016 Wainberg MA, Hull MW, Girard PM, Montaner JS. Achieving the 90-90-90 target: incentives for HIV testing. The Lancet. Infectious Diseases. 16: 1215-1216. PMID 27788971 DOI: 10.1016/S1473-3099(16)30383-8  0.469
2016 Brenner B, Wainberg MA. We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance. Aids (London, England). 30: 2725-2727. PMID 27782967 DOI: 10.1097/Qad.0000000000001234  0.5
2016 Han YS, Penthala NR, Oliveira M, Mesplède T, Xu H, Quan Y, Crooks PA, Wainberg MA. Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. Journal of Medical Virology. PMID 27509184 DOI: 10.1002/Jmv.24660  0.335
2016 Isitman G, Lisovsky I, Tremblay-McLean A, Kovacs C, Harris M, Routy JP, Bruneau J, Wainberg MA, Tremblay C, Bernard NF. Antibody dependent cellular cytotoxicity activity of effector cells from HIV infected Elite and Viral Controllers. Aids Research and Human Retroviruses. PMID 27499379 DOI: 10.1089/Aid.2016.0157  0.474
2016 Mesplède T, Wainberg MA. Will LEDGIN molecules be able to play a role in a cure for HIV infection? Ebiomedicine. 8: 14-5. PMID 27428407 DOI: 10.1016/J.Ebiom.2016.05.007  0.524
2016 Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Research. PMID 27422477 DOI: 10.1016/J.Virusres.2016.07.006  0.512
2016 Oliveira M, Ibanescu RI, Pham HT, Brenner B, Mesplède T, Wainberg MA. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. Aids (London, England). PMID 27367488 DOI: 10.1097/Qad.0000000000001191  0.48
2016 Han YS, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes indrug resistance against integrase inhibitors. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. PMID 27353185 DOI: 10.1016/J.Meegid.2016.06.047  0.54
2016 Liang C, Wainberg MA, Das AT, Berkhout B. CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology. 13: 37. PMID 27230886 DOI: 10.1186/S12977-016-0270-0  0.52
2016 Pham HT, Mesplède T, Wainberg MA. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Retrovirology. 13: 31. PMID 27130466 DOI: 10.1186/S12977-016-0265-X  0.565
2016 Anstett K, Cutillas V, Fusco R, Mesplède T, Wainberg MA. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. The Journal of Antimicrobial Chemotherapy. PMID 27084918 DOI: 10.1093/Jac/Dkw109  0.547
2016 Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C. CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Reports. PMID 27068471 DOI: 10.1016/J.Celrep.2016.03.042  0.581
2016 Wainberg MA, Han YS, Mesplède T. Might dolutegravir be part of a functional cure for HIV? Canadian Journal of Microbiology. 1-8. PMID 27031127 DOI: 10.1139/Cjm-2015-0725  0.568
2016 Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. The Journal of Antimicrobial Chemotherapy. PMID 27029845 DOI: 10.1093/Jac/Dkw071  0.421
2016 Otis J, McFadyen A, Haig T, Blais M, Cox J, Brenner B, Rousseau R, Émond G, Roger M, Wainberg M. Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada. Aids and Behavior. PMID 26961381 DOI: 10.1007/S10461-016-1344-7  0.496
2016 Wainberg MA. Early HIV treatment to forestall drug resistance. The Lancet. Infectious Diseases. PMID 26831126 DOI: 10.1016/S1473-3099(16)00013-X  0.527
2016 Wainberg MA. Interview with Professor Mark A Wainberg Future Virology. 11: 607-609. DOI: 10.2217/Fvl-2016-0085  0.508
2016 Wainberg M. HIV PrEP opens the door to STDs. The cons Journal of Virus Eradication. 2: 4. DOI: 10.1016/S2055-6640(20)31232-2  0.522
2016 Mesplède T, Liang J, Anstett K, Osman N, Pham HT, Wainberg MA. Selection of the R263K and H51Y resistance substitutions for DTG causes diminished integration and explains the lack of clinically significant drug resistance to this compound Journal of Virus Eradication. 2: 27. DOI: 10.1016/S2055-6640(20)31142-0  0.338
2016 Mesplède T, Wainberg MA. The R263K resistance substitution decreases levels of integrated HIV DNA over time Journal of Virus Eradication. 2: 12. DOI: 10.1016/S2055-6640(20)31114-6  0.503
2016 Zhang H, Han YS, Wainberg MA, Yue JM. Flueggethers B-D, Securinega alkaloids with rare oligomerizing pattern from Flueggea virosa Tetrahedron Letters. 57: 1798-1800. DOI: 10.1016/J.Tetlet.2016.03.034  0.354
2016 Mesplède T, Wainberg MA. Will LEDGIN molecules be able to play a role in a cure for HIV infection? Ebiomedicine. 8: 14-15. DOI: 10.1016/j.ebiom.2016.05.007  0.371
2016 Zhang H, Zhang C, Han Y, Wainberg MA, Yue J. ChemInform Abstract: New Securinega Alkaloids with anti-HIV Activity from Flueggea virosa. Cheminform. 47. DOI: 10.1002/CHIN.201619175  0.379
2015 Wainberg MA, Han YS. HIV-1 resistance to dolutegravir: update and new insights. Journal of Virus Eradication. 1: 13-6. PMID 27482391 DOI: 10.1016/S2055-6640(20)31150-X  0.47
2015 Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, ... ... Wainberg MA, et al. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. Plos One. 10: e0145772. PMID 26717411 DOI: 10.1371/Journal.Pone.0145772  0.51
2015 Wainberg MA, Mesplede T. Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy. Journal of the International Aids Society. 18: 20824. PMID 26642452 DOI: 10.7448/Ias.18.1.20824  0.47
2015 Zhang H, Zhu KK, Han YS, Luo C, Wainberg MA, Yue JM. Flueggether A and Virosinine A, Anti-HIV Alkaloids from Flueggea virosa. Organic Letters. PMID 26632657 DOI: 10.1021/Acs.Orglett.5B03320  0.417
2015 Wainberg MA, Kippax S, Bras M, Sow PS. Has the world ceased to care about HIV? And what can we do about it? Journal of the International Aids Society. 18: 20818. PMID 26632480 DOI: 10.7448/Ias.18.1.20818  0.374
2015 Lever A, Wainberg M. World AIDS Day 2015. Retrovirology. 12: 101. PMID 26627883 DOI: 10.1186/S12977-015-0228-7  0.528
2015 Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, ... ... Wainberg MA, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. The New England Journal of Medicine. 373: 2237-2246. PMID 26624850 DOI: 10.1056/NEJMoa1506273  0.423
2015 Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA. Identification of a pyridoxine-derived small-molecule inhibitor targeting dengue virus RNA-dependent RNA polymerase. Antimicrobial Agents and Chemotherapy. PMID 26574011 DOI: 10.1128/Aac.02203-15  0.425
2015 Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiology. 10: 1773-82. PMID 26517190 DOI: 10.2217/Fmb.15.106  0.567
2015 Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Journal of Virology. 89: 12002-13. PMID 26378179 DOI: 10.1128/Jvi.02131-15  0.595
2015 Oliveira M, Mesplède T, Moïsi D, Ibanescu RI, Brenner B, Wainberg MA. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. Aids (London, England). 29: 2255-60. PMID 26372484 DOI: 10.1097/Qad.0000000000000866  0.55
2015 Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA. The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high level viral replication and the development of high-level drug resistance. Journal of Virology. PMID 26311878 DOI: 10.1128/Jvi.01881-15  0.503
2015 Anstett K, Fusco R, Cutillas V, Mesplède T, Wainberg MA. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Journal of Virology. 89: 10482-8. PMID 26246578 DOI: 10.1128/Jvi.01725-15  0.555
2015 Mesplède T, Quashie PK, Hassounah S, Osman N, Han Y, Liang J, Singhroy DN, Wainberg MA. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. Aids (London, England). 29: 1459-66. PMID 26244385 DOI: 10.1097/Qad.0000000000000752  0.577
2015 Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, Wainberg MA, Bruneau J, Bernard NF. Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity. Aids (London, England). 29: 1433-43. PMID 26244383 DOI: 10.1097/Qad.0000000000000729  0.351
2015 Mesplède T, Wainberg MA. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses. 7: 3703-18. PMID 26198244 DOI: 10.3390/V7072790  0.525
2015 Han YS, Xiao WL, Xu H, Kramer VG, Quan Y, Mesplède T, Oliveira M, Colby-Germinario SP, Sun HD, Wainberg MA. Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor. Antiviral Chemistry & Chemotherapy. 24: 28-38. PMID 26149264 DOI: 10.1177/2040206614566580  0.533
2015 Osman N, Mesplède T, Quashie PK, Oliveira M, Zanichelli V, Wainberg MA. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. The Journal of Antimicrobial Chemotherapy. 70: 2810-5. PMID 26142476 DOI: 10.1093/Jac/Dkv176  0.591
2015 Quashie PK, Han YS, Hassounah S, Mesplède T, Wainberg MA. Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. Plos One. 10: e0128310. PMID 26046987 DOI: 10.1371/Journal.Pone.0128310  0.474
2015 Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA. HIV-1 Group O Resistance Against Integrase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999). 70: 9-15. PMID 26017662 DOI: 10.1097/Qai.0000000000000698  0.514
2015 Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA. A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. Journal of Medical Virology. 87: 2054-60. PMID 25989218 DOI: 10.1002/Jmv.24271  0.549
2015 Wainberg MA, Han YS. Will drug resistance against dolutegravir in initial therapy ever occur? Frontiers in Pharmacology. 6: 90. PMID 25972810 DOI: 10.3389/Fphar.2015.00090  0.464
2015 Yu JH, Wang GC, Han YS, Wu Y, Wainberg MA, Yue JM. Limonoids with Anti-HIV Activity from Cipadessa cinerascens. Journal of Natural Products. 78: 1243-52. PMID 25970729 DOI: 10.1021/Acs.Jnatprod.5B00025  0.4
2015 Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau-Betzer F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, ... Wainberg MA, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. Retrovirology. 12: 30. PMID 25889234 DOI: 10.1186/S12977-015-0159-3  0.593
2015 Mesplède T, Moïsi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, Wainberg MA. Dolutegravir inhibits HIV-1 Env evolution in primary human cells. Aids (London, England). 29: 659-65. PMID 25849829 DOI: 10.1097/Qad.0000000000000606  0.518
2015 Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology. 12: 22. PMID 25808449 DOI: 10.1186/S12977-015-0150-Z  0.513
2015 Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, Wainberg MA. Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor. Antimicrobial Agents and Chemotherapy. 59: 3189-96. PMID 25779585 DOI: 10.1128/Aac.00315-15  0.493
2015 Wainberg MA. Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 60: 1550-1. PMID 25681379 DOI: 10.1093/Cid/Civ107  0.436
2015 Singhroy DN, Wainberg MA, Mesplède T. Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrobial Agents and Chemotherapy. 59: 2882-5. PMID 25666155 DOI: 10.1128/Aac.05181-14  0.532
2015 Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. Journal of Virology. 89: 4681-4. PMID 25653436 DOI: 10.1128/Jvi.03485-14  0.389
2015 Wares M, Hassounah S, Mesplède T, Sandstrom PA, Wainberg MA. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. Antimicrobial Agents and Chemotherapy. 59: 1942-9. PMID 25583721 DOI: 10.1128/Aac.04829-14  0.608
2015 Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, Wainberg MA. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. Journal of Virology. 89: 3163-75. PMID 25552724 DOI: 10.1128/Jvi.03353-14  0.585
2015 Kramer VG, Hassounah S, Colby-Germinario SP, Oliveira M, Lefebvre E, Mesplède T, Wainberg MA. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. The Journal of Antimicrobial Chemotherapy. 70: 750-6. PMID 25433008 DOI: 10.1093/Jac/Dku451  0.481
2015 Cutillas V, Mesplede T, Anstett K, Hassounah S, Wainberg MA. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrobial Agents and Chemotherapy. 59: 310-6. PMID 25348535 DOI: 10.1128/Aac.04274-14  0.55
2015 Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. The Journal of Antimicrobial Chemotherapy. 70: 405-11. PMID 25281399 DOI: 10.1093/Jac/Dku387  0.447
2015 Wainberg MA. Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable? Journal of Infectious Diseases and Therapy. 3. DOI: 10.4172/2332-0877.1000208  0.517
2015 Kramer VG, Wainberg MA. Resistance against inhibitors of HIV-1 entry into target cells Future Virology. 10: 97-112. DOI: 10.2217/Fvl.14.104  0.504
2015 Zhang H, Zhang CR, Han YS, Wainberg MA, Yue JM. New Securinega alkaloids with anti-HIV activity from Flueggea virosa Rsc Advances. 5: 107045-107053. DOI: 10.1039/C5Ra22191A  0.371
2015 Wainberg MA, Osman N, Pham HT, Spira B, Mesplede T. Impairment of the long-term ability of dolutegravir-resistant viruses to integrate Journal of Virus Eradication. 1: 40-41. DOI: 10.1016/S2055-6640(20)31413-8  0.309
2015 Zhang H, Han Y, Wainberg MA, Yue J. Anti-HIV Securinega alkaloid oligomers from Flueggea virosa Tetrahedron. 71: 3671-3679. DOI: 10.1016/J.Tet.2014.10.064  0.421
2015 Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA. A resveratrol analog termed 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor Journal of Medical Virology. DOI: 10.1002/jmv.24271  0.369
2014 Hankins CA, Wainberg MA, Weiss RA. In tribute to Joep Lange. Retrovirology. 11: 82. PMID 25927561 DOI: 10.1186/S12977-014-0082-Z  0.55
2014 Wainberg MA, Lever AM. How will the ebola crisis impact the HIV epidemic? Retrovirology. 11: 110. PMID 25472763 DOI: 10.1186/S12977-014-0110-Z  0.544
2014 Wainberg MA, Kippax S, Bras M, Sow PS. HIV and Ebola: similarities and differences. Journal of the International Aids Society. 17: 19896. PMID 25466882 DOI: 10.7448/Ias.17.1.19896  0.538
2014 Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Brenner B, Wainberg M. HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. Journal of the International Aids Society. 17: 19738. PMID 25397483 DOI: 10.7448/Ias.17.4.19738  0.528
2014 Kramer V, Hassounah S, Colby-Germinario S, Mesplède T, Lefebvre E, Wainberg M. Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc. Journal of the International Aids Society. 17: 19531. PMID 25394040 DOI: 10.7448/Ias.17.4.19531  0.53
2014 Wainberg M, Anstett K, Mesplede T, Quashie P, Han Y, Oliveira M. The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. Journal of the International Aids Society. 17: 19518. PMID 25394027 DOI: 10.7448/Ias.17.4.19518  0.505
2014 Liu CP, Xu JB, Han YS, Wainberg MA, Yue JM. Trichiconins A-C, limonoids with new carbon skeletons from Trichilia connaroides. Organic Letters. 16: 5478-81. PMID 25296007 DOI: 10.1021/Ol5027552  0.304
2014 Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C. A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load. Plos One. 9: e109420. PMID 25295725 DOI: 10.1371/Journal.Pone.0109420  0.553
2014 Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA. Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines. Virology Journal. 11: 177. PMID 25287969 DOI: 10.1186/1743-422X-11-177  0.557
2014 Zhao JX, Liu CP, Qi WY, Han ML, Han YS, Wainberg MA, Yue JM. Eurifoloids A-R, structurally diverse diterpenoids from Euphorbia neriifolia. Journal of Natural Products. 77: 2224-33. PMID 25252924 DOI: 10.1021/Np5004752  0.323
2014 Bastarache SM, Mesplède T, Donahue DA, Sloan RD, Wainberg MA. Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency. Viruses. 6: 3487-99. PMID 25243372 DOI: 10.3390/V6093487  0.592
2014 Depatureaux A, Quashie PK, Mesplède T, Han Y, Koubi H, Plantier JC, Oliveira M, Moisi D, Brenner B, Wainberg MA. HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. Antimicrobial Agents and Chemotherapy. 58: 7141-50. PMID 25224008 DOI: 10.1128/Aac.03819-14  0.515
2014 Martin E, Carlson JM, Le AQ, Chopera DR, McGovern R, Rahman MA, Ng C, Jessen H, Kelleher AD, Markowitz M, Allen TM, Milloy MJ, Carrington M, Wainberg MA, Brumme ZL. Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology. 11: 64. PMID 25212686 DOI: 10.1186/S12977-014-0064-1  0.476
2014 Mesplède T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses. 6: 3377-85. PMID 25166745 DOI: 10.3390/V6093377  0.544
2014 Lafeuillade A, Wainberg M, Gougeon ML, Loes SK, Halfon P, Tissot-Dupont H. Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic. Aids Research and Therapy. 11: 28. PMID 25165483 DOI: 10.1186/1742-6405-11-28  0.518
2014 Wainberg MA, Kippax S, Bras M, Salif Sow P. The 20th International AIDS Conference: where do we go from here? Journal of the International Aids Society. 17: 19331. PMID 25043381 DOI: 10.7448/Ias.17.1.19331  0.356
2014 Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N. Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. Journal of the International Aids Society. 17: 18944. PMID 24998532 DOI: 10.7448/Ias.17.1.18944  0.515
2014 Papuchon J, Pinson P, Guidicelli GL, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin JL, Baril JG, Routy JP, Wainberg M, Fleury H. Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study. Plos One. 9: e100452. PMID 24964202 DOI: 10.1371/Journal.Pone.0100452  0.461
2014 Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. Journal of Virology. 88: 9683-92. PMID 24920794 DOI: 10.1128/Jvi.00947-14  0.587
2014 Mesplède T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. The Journal of Antimicrobial Chemotherapy. 69: 2733-40. PMID 24917583 DOI: 10.1093/Jac/Dku199  0.589
2014 Kramer VG, Varsaneux O, Oliviera M, Colby-Germinario SP, Mesplède T, Wainberg MA. Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 7-14. PMID 24872133 DOI: 10.1097/Qai.0000000000000223  0.465
2014 Xu HT, Colby-Germinario SP, Oliveira M, Rajotte D, Bethell R, Wainberg MA. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 58: 4515-26. PMID 24867966 DOI: 10.1128/Aac.02729-14  0.561
2014 Xu JB, Zhang H, Gan LS, Han YS, Wainberg MA, Yue JM. Logeracemin A, an anti-HIV Daphniphyllum alkaloid dimer with a new carbon skeleton from Daphniphyllum longeracemosum. Journal of the American Chemical Society. 136: 7631-3. PMID 24828017 DOI: 10.1021/Ja503995B  0.41
2014 Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? The Journal of Antimicrobial Chemotherapy. 69: 1742-7. PMID 24603962 DOI: 10.1093/Jac/Dku058  0.441
2014 Mesplède T, Quashie PK, Zanichelli V, Wainberg MA. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Annals of Medicine. 46: 123-9. PMID 24579911 DOI: 10.3109/07853890.2014.883169  0.55
2014 Oliveira M, Mesplède T, Quashie PK, Moïsi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. Aids (London, England). 28: 813-9. PMID 24463394 DOI: 10.1097/Qad.0000000000000199  0.453
2014 Wares M, Mesplède T, Quashie PK, Osman N, Han Y, Wainberg MA. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology. 11: 7. PMID 24433497 DOI: 10.1186/1742-4690-11-7  0.521
2014 Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. Aids (London, England). 28: 317-23. PMID 24326355 DOI: 10.1097/Qad.0000000000000168  0.589
2014 Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity. Journal of Virology. 88: 1536-47. PMID 24227862 DOI: 10.1128/Jvi.02904-13  0.423
2014 Quan Y, Xu H, Wainberg MA. Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV. The Journal of Antimicrobial Chemotherapy. 69: 21-7. PMID 23963235 DOI: 10.1093/Jac/Dkt326  0.539
2014 Wainberg M. Ten big challenges ahead Bmc Infectious Diseases. 14. DOI: 10.1186/1471-2334-14-S2-S1  0.543
2013 Mesplède T, Wainberg MA. Integrase Strand Transfer Inhibitors in HIV Therapy. Infectious Diseases and Therapy. 2: 83-93. PMID 25134473 DOI: 10.1007/S40121-013-0020-8  0.56
2013 Tremblay C, Hardy I, Lalonde R, Trottier B, Tsarevsky I, Vézina LP, Roger M, Wainberg M, Baril JG. HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 24: 202-8. PMID 24489562 DOI: 10.1155/2013/982759  0.389
2013 Wainberg MA, Mesplède T, Raffi F. What if HIV were unable to develop resistance against a new therapeutic agent? Bmc Medicine. 11: 249. PMID 24267867 DOI: 10.1186/1741-7015-11-249  0.537
2013 Wainberg MA, Lever A. World AIDS Day: together we will stop HIV transmission and conquer AIDS. Retrovirology. 10: 129. PMID 24229411 DOI: 10.1186/1742-4690-10-129  0.497
2013 Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrobial Agents and Chemotherapy. 57: 6223-35. PMID 24080645 DOI: 10.1128/Aac.01835-13  0.515
2013 Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, Petropoulos CJ, Wainberg MA. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 57: 5649-57. PMID 24002090 DOI: 10.1128/Aac.01536-13  0.511
2013 Heredia A, Davis CE, Reitz MS, Le NM, Wainberg MA, Foulke JS, Wang LX, Redfield RR. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1. The Journal of Infectious Diseases. 208: 2085-94. PMID 23922365 DOI: 10.1093/Infdis/Jit395  0.443
2013 Brenner B, Wainberg MA, Roger M. Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. Aids (London, England). 27: 1045-57. PMID 23902920 DOI: 10.1097/Qad.0B013E32835Cffd9  0.431
2013 Gupta RK, Van de Vijver DA, Manicklal S, Wainberg MA. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology. 10: 82. PMID 23902855 DOI: 10.1186/1742-4690-10-82  0.462
2013 Singhroy DN, Mesplède T, Sabbah A, Quashie PK, Falgueyret JP, Wainberg MA. Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. Retrovirology. 10: 73. PMID 23866860 DOI: 10.1186/1742-4690-10-73  0.501
2013 McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi D, Asahchop EL, Brenner BG, Harrigan PR, Xu H, Wainberg MA. Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 57: 4681-8. PMID 23856772 DOI: 10.1128/Aac.01029-13  0.522
2013 Donahue DA, Bastarache SM, Sloan RD, Wainberg MA. Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. Journal of Virology. 87: 9620-32. PMID 23804632 DOI: 10.1128/Jvi.01165-13  0.515
2013 Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. Journal of Acquired Immune Deficiency Syndromes (1999). 63: S248-54. PMID 23764643 DOI: 10.1097/Qai.0B013E3182986F96  0.474
2013 Invernizzi CF, Coutsinos D, Oliveira M, Schildknecht RS, Xu H, Gaseitsiwe S, Moisi D, Brenner BG, Wainberg MA. The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites. The Journal of Antimicrobial Chemotherapy. 68: 2192-6. PMID 23749954 DOI: 10.1093/Jac/Dkt204  0.462
2013 Lisovsky I, Schader SM, Sloan RD, Oliveira M, Coutsinos D, Bernard NF, Wainberg MA. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction. Intervirology. 56: 258-64. PMID 23689841 DOI: 10.1159/000348513  0.828
2013 Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sönnerborg A, Nachega JB. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. The Journal of Infectious Diseases. 207: S101-6. PMID 23687287 DOI: 10.1093/Infdis/Jit108  0.502
2013 Sloan RD, Kuhl BD, Mesplède T, Münch J, Donahue DA, Wainberg MA. Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. Journal of Virology. 87: 8110-23. PMID 23678185 DOI: 10.1128/Jvi.00815-13  0.442
2013 Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, Wu G, Wainberg MA, Yao X. Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrobial Agents and Chemotherapy. 57: 3547-54. PMID 23669388 DOI: 10.1128/Aac.00100-13  0.578
2013 Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrobial Agents and Chemotherapy. 57: 3100-9. PMID 23612196 DOI: 10.1128/Aac.00348-13  0.792
2013 Han YS, Xiao WL, Quashie PK, Mesplède T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Research. 98: 441-8. PMID 23583286 DOI: 10.1016/J.Antiviral.2013.04.001  0.515
2013 Berkhout B, Lever A, Wainberg M, Fassati A, Borrow P, Fujii M. Monsef Benkirane awarded 2013 Ming K. Jeang Foundation Retrovirology Prize: landmark HIV-1 research honoured. Retrovirology. 10: 38. PMID 23561838 DOI: 10.1186/1742-4690-10-38  0.42
2013 Heidari S, Kippax S, Sow PS, Wainberg MA. Women hold up half the sky - and half the burden of the HIV epidemic. Journal of the International Aids Society. 16: 18608. PMID 23473096 DOI: 10.7448/Ias.16.1.18608  0.451
2013 Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 10: 22. PMID 23432922 DOI: 10.1186/1742-4690-10-22  0.535
2013 Sloan RD, Wainberg MA. Harnessing the therapeutic potential of host antiviral restriction factors that target HIV. Expert Review of Anti-Infective Therapy. 11: 1-4. PMID 23428096 DOI: 10.1586/Eri.12.146  0.473
2013 Wainberg MA. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. Hiv/Aids (Auckland, N.Z.). 5: 41-9. PMID 23413112 DOI: 10.2147/Hiv.S32377  0.486
2013 Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 10: 11. PMID 23375003 DOI: 10.1186/1742-4690-10-11  0.472
2013 Parsons MS, Center RJ, Routy JP, Rouleau D, Leblanc R, Wainberg MA, Tremblay CL, Zannou MD, Kent SJ, Grant MD, Bernard NF. Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire. Aids Research and Human Retroviruses. 29: 778-83. PMID 23265432 DOI: 10.1089/Aid.2012.0094  0.447
2013 Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. Aids (London, England). 27: 879-87. PMID 23262501 DOI: 10.1097/Qad.0B013E32835D9F6D  0.504
2013 Quashie PK, Mesplède T, Wainberg MA. Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases. 26: 43-9. PMID 23242340 DOI: 10.1097/QCO.0b013e32835ba81c  0.384
2013 Quashie PK, Mesplède T, Wainberg MA. HIV Drug Resistance and the Advent of Integrase Inhibitors. Current Infectious Disease Reports. 15: 85-100. PMID 23180144 DOI: 10.1007/s11908-012-0305-1  0.368
2013 Zaharatos GJ, Wainberg MA. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Annals of Medicine. 45: 236-41. PMID 23157601 DOI: 10.3109/07853890.2012.732704  0.529
2013 Asahchop EL, Oliveira M, Quashie PK, Moisi D, Martinez-Cajas JL, Brenner BG, Tremblay CL, Wainberg MA. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor. The Journal of Antimicrobial Chemotherapy. 68: 105-12. PMID 22945918 DOI: 10.1093/jac/dks342  0.478
2013 Spira SC, Wainberg MA. HIV vaccine triage: Halakhic considerations The Jewish Law Annual: Volume Twenty. 235-278. DOI: 10.4324/9780203714201  0.308
2013 Raffi F, Wainberg MA. Antiretroviral therapy with integrase inhibitors: More options Virologie. 17: 54-60. DOI: 10.1684/Vir.2013.0479  0.454
2013 Donahue DA, Bastarache SM, Sloan RD, Wainberg MA. Latent HIV-1 can be reactivated by superinfection in a Tat-dependent manner, which can lead to the emergence of recombinant viruses Retrovirology. 10. DOI: 10.1186/1742-4690-10-S1-P27  0.531
2013 Brenner BG, Roger M, Otis J, Wainberg MA. Population-level phylogenetic surveillance of the Montreal men who have sex with men epidemic 2002–12 The Lancet. 382: S18. DOI: 10.1016/S0140-6736(13)62266-7  0.51
2013 Shang S, Han Y, Shi Y, Du X, Liang C, Wainberg MA, Gao Z, Xiao W, Sun H. Four new lignans from the leaves and stems of Schisandra propinqua var. sinensis Natural Products and Bioprospecting. 3: 56-60. DOI: 10.1007/S13659-013-0017-8  0.346
2012 Wainberg MA. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica. 2012: 238278. PMID 24278679 DOI: 10.6064/2012/238278  0.412
2012 Raffi F, Wainberg MA. Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology. 9: 110. PMID 23253887 DOI: 10.1186/1742-4690-9-110  0.431
2012 Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y, Quan Y, Wainberg MA. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. Journal of Virology. 86: 12983-90. PMID 22993165 DOI: 10.1128/Jvi.02005-12  0.494
2012 Wainberg MA, Mesplède T, Quashie PK. The development of novel HIV integrase inhibitors and the problem of drug resistance. Current Opinion in Virology. 2: 656-62. PMID 22989757 DOI: 10.1016/J.Coviro.2012.08.007  0.451
2012 Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, et al. Biochemical mechanism of HIV-1 resistance to rilpivirine. The Journal of Biological Chemistry. 287: 38110-23. PMID 22955279 DOI: 10.1074/Jbc.M112.398180  0.312
2012 Wainberg MA, Brenner BG. The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs. Molecular Biology International. 2012: 256982. PMID 22792462 DOI: 10.1155/2012/256982  0.497
2012 Mesplède T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Current Opinion in Hiv and Aids. 7: 401-8. PMID 22789986 DOI: 10.1097/COH.0b013e328356db89  0.444
2012 Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacological Reviews. 64: 803-33. PMID 22759796 DOI: 10.1124/Pr.111.005553  0.508
2012 Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 56: 5000-8. PMID 22733071 DOI: 10.1128/Aac.00591-12  0.485
2012 Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. Journal of Virology. 86: 8422-31. PMID 22623801 DOI: 10.1128/Jvi.00271-12  0.426
2012 Schader SM, Colby-Germinario SP, Quashie PK, Oliveira M, Ibanescu RI, Moisi D, Mespléde T, Wainberg MA. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrobial Agents and Chemotherapy. 56: 4257-67. PMID 22615295 DOI: 10.1128/Aac.00639-12  0.847
2012 Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrobial Agents and Chemotherapy. 56: 4154-60. PMID 22615275 DOI: 10.1128/Aac.00409-12  0.819
2012 Han YS, Quashie P, Mesplede T, Xu H, Mekhssian K, Fenwick C, Wainberg MA. A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence. Journal of Virological Methods. 184: 34-40. PMID 22584270 DOI: 10.1016/J.Jviromet.2012.05.003  0.511
2012 Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 54: S245-9. PMID 22544182 DOI: 10.1093/Cid/Cis206  0.489
2012 Wainberg MA, Dascal A, Mendelson J. Anti-retroviral strategies for AIDS and related diseases. The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses. 2: 121-8. PMID 22529721 DOI: 10.1155/1991/487657  0.592
2012 Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. Bmc Medicine. 10: 34. PMID 22498430 DOI: 10.1186/1741-7015-10-34  0.417
2012 Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, Moisi D, Mendelson E, Grossman Z, Brenner BG. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. The Journal of Antimicrobial Chemotherapy. 67: 988-94. PMID 22315096 DOI: 10.1093/Jac/Dkr582  0.521
2012 Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. The Viral Protein Tat Can Inhibit the Establishment of HIV-1 Latency Journal of Virology. 86: 3253-3263. PMID 22238306 DOI: 10.1128/Jvi.06648-11  0.476
2012 Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrobial Agents and Chemotherapy. 56: 751-6. PMID 22123692 DOI: 10.1128/Aac.05821-11  0.831
2012 Mesplede T, Quashie P, Oliveira M, Underwood M, Wang R, Fujiwara T, Seki T, Wainberg M. Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness Journal of the International Aids Society. 15. DOI: 10.7448/Ias.15.6.18113  0.576
2012 Wainberg M. Pre-exposure prophylaxis against HIV: pros and cons Retrovirology. 9. DOI: 10.1186/1742-4690-9-S1-I6  0.497
2012 Singh K, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Xu H, Wainberg MA, Marchand B, Sarafianos SG. Biochemical mechanism of clinical resistance to rilpivirine Bmc Infectious Diseases. 12: P94. DOI: 10.1186/1471-2334-12-S1-P94  0.59
2011 Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. Journal of Virology. 86: 2696-705. PMID 22205735 DOI: 10.1128/Jvi.06591-11  0.538
2011 Kuhl BD, Cheng V, Donahue DA, Sloan RD, Liang C, Wilkinson J, Wainberg MA. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism. Plos One. 6: e27660. PMID 22110710 DOI: 10.1371/Journal.Pone.0027660  0.439
2011 Whitney JB, Lim SY, Wainberg MA. Evolutionary mechanisms of retroviral persistence. Aids Reviews. 13: 234-9. PMID 21975359  0.647
2011 Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. Journal of Virology. 85: 11300-8. PMID 21849444 DOI: 10.1128/Jvi.05584-11  0.486
2011 Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. The New England Journal of Medicine. 365: 637-46. PMID 21848464 DOI: 10.1056/Nejmra1004180  0.584
2011 Poon AF, McGovern RA, Mo T, Knapp DJ, Brenner B, Routy JP, Wainberg MA, Harrigan PR. Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data. Aids (London, England). 25: 2019-26. PMID 21832936 DOI: 10.1097/Qad.0B013E32834B643C  0.468
2011 Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, Ferns B, Garson J, Gomes P, Gonçalves F, Gottlieb G, Kupfer B, Ruelle J, Rodes B, Soriano V, ... Wainberg M, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. Journal of Clinical Microbiology. 49: 3491-7. PMID 21813718 DOI: 10.1128/Jcm.02389-10  0.54
2011 Kuhl BD, Sloan RD, Donahue DA, Liang C, Wainberg MA. Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation. Virology. 417: 353-61. PMID 21757214 DOI: 10.1016/J.Virol.2011.06.012  0.423
2011 Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. The Journal of Antimicrobial Chemotherapy. 66: 2346-9. PMID 21750100 DOI: 10.1093/Jac/Dkr291  0.558
2011 Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection Retrovirology. 8. PMID 21722380 DOI: 10.1186/1742-4690-8-52  0.46
2011 Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez-Cajas JL, Brenner BG, Wainberg MA. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. Plos One. 6: e20208. PMID 21655292 DOI: 10.1371/Journal.Pone.0020208  0.468
2011 Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. Aids (London, England). 25: 1585-94. PMID 21633286 DOI: 10.1097/Qad.0B013E3283491F89  0.842
2011 Wainberg MA, Jeang KT. XMRV as a human pathogen? Cell Host and Microbe. 9: 260-262. PMID 21501825 DOI: 10.1016/J.Chom.2011.04.001  0.305
2011 Heidari S, Eckert MJ, Kippax S, Karim QA, Sow PS, Wainberg MA. Time for gender mainstreaming in editorial policies. Journal of the International Aids Society. 14: 11. PMID 21385405 DOI: 10.1186/1758-2652-14-11  0.38
2011 Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. Journal of Medical Virology. 83: 751-9. PMID 21360548 DOI: 10.1002/Jmv.22047  0.453
2011 Wainberg MA. AIDS: Drugs that prevent HIV infection Nature. 469: 306-307. PMID 21248832 DOI: 10.1038/469306A  0.529
2011 Kuhl BD, Cheng V, Wainberg MA, Liang C. Tetherin and its viral antagonists Journal of Neuroimmune Pharmacology. 6: 188-201. PMID 21222046 DOI: 10.1007/S11481-010-9256-1  0.342
2011 Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA. Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef. Journal of Virology. 85: 2828-36. PMID 21209113 DOI: 10.1128/Jvi.01854-10  0.467
2011 Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni Td, Tremblay CL. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrobial Agents and Chemotherapy. 55: 600-7. PMID 21135184 DOI: 10.1128/Aac.01192-10  0.492
2011 Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. Journal of Virology. 85: 1224-36. PMID 21084468 DOI: 10.1128/Jvi.01635-10  0.535
2011 Rios A, Quesada J, Anderson D, Goldstein A, Fossum T, Colby-Germinario S, Wainberg MA. Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors. Virus Research. 155: 189-94. PMID 20937333 DOI: 10.1016/J.Virusres.2010.10.004  0.498
2011 Roldan A, Liang C, Wainberg MA. Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag protein Virus Research. 155: 98-105. PMID 20851722 DOI: 10.1016/J.Virusres.2010.09.005  0.439
2011 Wainberg MA, Field HJ. Proof of principle: Antiretroviral drugs can prevent sexual transmission of HIV-1 Future Virology. 6: 549-551. DOI: 10.2217/Fvl.11.37  0.465
2011 Michaud V, Turgeon J, Flockhart D, Wainberg MA. Role of pharmacogenetics in the metabolism and transport of antiretroviral drugs Virologie. 15: 157-174. DOI: 10.1684/Vir.2011.0405  0.382
2011 Sloan RD, Kuhl BD, Münch J, Donahue DA, Wainberg MA. Cell-to-cell transmission of HIV-1 between CD4+T-cells involves clathrin-mediated endocytosis Retrovirology. 8. DOI: 10.1186/1742-4690-8-S2-P63  0.437
2011 Wainberg MA. Interactions of different drug resistance mutations in HIV Reverse Transcriptase in defining patterns of drug resistance Retrovirology. 8. DOI: 10.1186/1742-4690-8-S2-O14  0.55
2011 Wainberg MA, Toni T, Brenner BG. 172 Monitoring HIV Drug Resistance as a Guide to Understanding Viral Pathogenesis Jaids Journal of Acquired Immune Deficiency Syndromes. 56: 72. DOI: 10.1097/01.Qai.0000397356.68792.95  0.573
2011 Schader SM, Wainberg MA. Insights into HIV-1 pathogenesis through drug discovery: 30 years of basic research and concerns for the future Hiv and Aids Review. 10: 91-98. DOI: 10.1016/J.Hivar.2011.09.003  0.837
2010 Rachlis A, Harris M, Lalonde R, Shafran SD, Tremblay C, Wainberg MA, Walmsley S. Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 21: 159-72. PMID 22132003 DOI: 10.1155/2010/303474  0.506
2010 Wainberg MA, Brenner BG. Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses. 2: 2493-508. PMID 21994627 DOI: 10.3390/v2112493  0.477
2010 Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology. 7: 115. PMID 21184674 DOI: 10.1186/1742-4690-7-115  0.5
2010 Xu HT, Quan Y, Asahchop E, Oliveira M, Moisi D, Wainberg MA. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology. 7: 80. PMID 20929562 DOI: 10.1186/1742-4690-7-80  0.568
2010 Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. The Journal of Antimicrobial Chemotherapy. 65: 2291-9. PMID 20852269 DOI: 10.1093/Jac/Dkq338  0.597
2010 van Marle G, Church DL, Nunweiler KD, Cannon K, Wainberg MA, Gill MJ. Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology. 7: 74. PMID 20836880 DOI: 10.1186/1742-4690-7-74  0.57
2010 Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. Aids (London, England). 24: 2171-9. PMID 20647908 DOI: 10.1097/Qad.0B013E32833Cf265  0.529
2010 Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. Journal of Virology. 84: 9210-6. PMID 20610719 DOI: 10.1128/Jvi.01164-10  0.487
2010 Asahchop EL, Oliveira M, Brenner BG, Martinez-Cajas JL, Toni Td, Ntemgwa M, Moisi D, Dandache S, Stranix B, Tremblay CL, Wainberg MA. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes. Antiviral Research. 87: 367-72. PMID 20541566 DOI: 10.1016/J.Antiviral.2010.06.001  0.549
2010 Wainberg MA, Shuldiner T, Dahl K, Gilmore N. Reconsidering the lifetime deferral of blood donation by men who have sex with men. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 182: 1321-4. PMID 20501780 DOI: 10.1503/Cmaj.091476  0.387
2010 Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, Wainberg MA. Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology. 7: 44. PMID 20465832 DOI: 10.1186/1742-4690-7-44  0.482
2010 Lisovsky I, Schader SM, Martinez-Cajas JL, Oliveira M, Moisi D, Wainberg MA. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrobial Agents and Chemotherapy. 54: 2878-85. PMID 20404123 DOI: 10.1128/Aac.01828-09  0.83
2010 Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrobial Agents and Chemotherapy. 54: 2401-8. PMID 20308384 DOI: 10.1128/Aac.01795-09  0.836
2010 Wainberg MA, Albert J. Can the further clinical development of bevirimat be justified? Aids. 24: 773-774. PMID 20154583 DOI: 10.1097/Qad.0B013E328331C83B  0.442
2010 Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antiviral Chemistry & Chemotherapy. 20: 117-31. PMID 20054099 DOI: 10.3851/Imp1443  0.573
2010 Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrobial Agents and Chemotherapy. 54: 1047-54. PMID 20038621 DOI: 10.1128/Aac.01537-09  0.805
2010 Willer DO, Guan Y, Luscher MA, Li B, Pilon R, Fournier J, Parenteau M, Wainberg MA, Sandstrom P, MacDonald KS. Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs. Journal of Virology. 84: 2304-17. PMID 20032177 DOI: 10.1128/Jvi.01995-09  0.327
2010 Cahn P, Wainberg MA. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine The Journal of Antimicrobial Chemotherapy. 65: 213-217. PMID 20007333 DOI: 10.1093/Jac/Dkp422  0.518
2010 Wainberg MA, Brenner BG. Role of HIV subtype diversity in the development of resistance to antiviral drugs Viruses. 2: 2493-2508. DOI: 10.3390/V2112493  0.563
2010 Bar-Magen T, Sloan RD, Wainberg MA. At the forefront of retrovirology research: Frontiers of Retrovirology Hiv Therapy. 4: 13-15. DOI: 10.2217/Hiv.09.54  0.322
2010 Sloan R, Kuhl B, Kramer V, Donahue D, Bar-Magen T, Tressler R, Wainberg M. HIV entry blocked by maraviroc can cause an overestimation of viral load Journal of the International Aids Society. 13: 1-1. DOI: 10.1186/1758-2652-13-S4-O46  0.534
2010 Kuhl B, Sloan R, Donahue D, Bar-Magen T, Liang C, Wainberg M. Tetherin restricts direct cell-cell viral transfer and transmission of HIV-1 Journal of the International Aids Society. 13: 1-1. DOI: 10.1186/1758-2652-13-S3-O8  0.513
2010 Wainberg MA, Toni T, Brenner BG. Use of new resistance markers to predict virologic response to antiretrovirals Retrovirology. 7. DOI: 10.1186/1742-4690-7-S1-I21  0.472
2010 Motura M, Salomon H, Moroni G, Wainberg M, Brinon MC. ChemInform Abstract: Synthesis, Lipophilicity and Anti-HIV Activity of a New Brominated Analogue of Zidovudine. Cheminform. 30: no-no. DOI: 10.1002/chin.199937239  0.374
2009 Rachlis A, Angel JB, Harris M, Shafran SD, Therrien R, Tremblay C, Wainberg MA. Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie MéDicale / Ammi Canada. 20: e67-80. PMID 20808458 DOI: 10.1155/2009/940745  0.516
2009 Toni TA, Brenner BG, Asahchop EL, Ntemgwa M, Moisi D, Wainberg MA. Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 54: 907-11. PMID 19995921 DOI: 10.1128/Aac.01080-09  0.582
2009 Wainberg MA. Two standards of care for HIV: Why are Africans being short-changed? Retrovirology. 6. PMID 19951412 DOI: 10.1186/1742-4690-6-109  0.399
2009 Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology. 6: 103. PMID 19906306 DOI: 10.1186/1742-4690-6-103  0.487
2009 Doualla-Bell F, Gaolathe T, Avalos A, Cloutier S, Ndwapi N, Holcroft C, Moffat H, Dickinson D, Essex M, Wainberg MA, Mine M. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. Journal of the International Aids Society. 12: 25. PMID 19852859 DOI: 10.1186/1758-2652-12-25  0.426
2009 Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. The Journal of Infectious Diseases. 200: 1202-6. PMID 19764886 DOI: 10.1086/605894  0.523
2009 Quan Y, Liang C, Brenner BG, Wainberg MA. Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants. The Journal of Infectious Diseases. 200: 1479-83. PMID 19758098 DOI: 10.1086/606117  0.619
2009 Colby-Germinario S, Rios A, Quesada J, Anderson D, Goldstein AL, Fossum T, Wainberg MA. HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase. Vaccine. 27: 6137-42. PMID 19715783 DOI: 10.1016/J.Vaccine.2009.08.028  0.507
2009 Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrobial Agents and Chemotherapy. 53: 4667-72. PMID 19704127 DOI: 10.1128/Aac.00800-09  0.817
2009 Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G, Pollack S, Kessner R, Wainberg MA, Avidor B. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel Journal of Medical Virology. 81: 1509-1512. PMID 19626612 DOI: 10.1002/Jmv.21567  0.476
2009 Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). Journal of the International Aids Society. 12: 11. PMID 19566959 DOI: 10.1186/1758-2652-12-11  0.486
2009 Rong L, Zhang J, Lu J, Pan Q, Lorgeoux RP, Aloysius C, Guo F, Liu SL, Wainberg MA, Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. Journal of Virology. 83: 7536-46. PMID 19474106 DOI: 10.1128/Jvi.00620-09  0.649
2009 Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrobial Agents and Chemotherapy. 53: 3611-9. PMID 19470514 DOI: 10.1128/Aac.00154-09  0.557
2009 Wainberg MA. Criminalizing HIV transmission may be a mistake Cmaj. 180: 688. PMID 19289817 DOI: 10.1503/Cmaj.090249  0.526
2009 Wainberg MA, Martinez-Cajas JL. Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease. Infectious Disorders Drug Targets. 9: 172-90. PMID 19275705 DOI: 10.2174/187152609787847668  0.515
2009 Oliveira M, Moisi D, Spira B, Cox S, Brenner BG, Wainberg MA. Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Antimicrobial Agents and Chemotherapy. 53: 1683-5. PMID 19223637 DOI: 10.1128/Aac.01168-08  0.416
2009 Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology. 6: 14. PMID 19210791 DOI: 10.1186/1742-4690-6-14  0.488
2009 Toni TA, Asahchop EL, Moisi D, Ntemgwa M, Oliveira M, Masquelier B, Brenner BG, Wainberg MA. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrobial Agents and Chemotherapy. 53: 1670-2. PMID 19171798 DOI: 10.1128/Aac.01494-08  0.577
2009 Wainberg MA. New findings on blockage of HIV-1 RNase H activity Aids. 23: 223-224. PMID 19098492 DOI: 10.1097/Qad.0B013E32831C5526  0.473
2009 Martínez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. Aids Reviews. 10: 212-23. PMID 19092977  0.45
2009 Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. Journal of Virology. 83: 2029-33. PMID 19073730 DOI: 10.1128/Jvi.01349-08  0.479
2009 Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection Methods in Molecular Biology. 485: 427-433. PMID 19020842 DOI: 10.1007/978-1-59745-170-3_29  0.517
2009 Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA. Transmission networks of drug resistance acquired in primary/early stage HIV infection. Aids (London, England). 22: 2509-15. PMID 19005274 DOI: 10.1097/Qad.0B013E3283121C90  0.473
2009 Wainberg MA. Perspectives on antiviral drug development Antiviral Research. 81: 1-5. PMID 18948140 DOI: 10.1016/J.Antiviral.2008.09.003  0.514
2009 Zhang J, Rong L, Wainberg MA, Liang C. Mechanistic study of BST-2 down-modulation by HIV-1 Vpu Retrovirology. 6. DOI: 10.1186/1742-4690-6-S2-P97  0.706
2009 Bar-Magen T, Sloan RD, McDonough EI, Faltenbacher V, Donahue DA, Kuhl BD, Xu H, Wainberg MA. Comparative biochemical analysis of wildtype and drug resistant HIV-1 integrase subtypes B and C Retrovirology. 6. DOI: 10.1186/1742-4690-6-S2-P6  0.464
2009 Wainberg MA, Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG. Biochemical and virological analysis of the preference for the K65R multi-resistance nucleoside mutation in subtype C viruses Retrovirology. 6. DOI: 10.1186/1742-4690-6-S2-I18  0.374
2008 Ntemgwa ML, Toni Td, Brenner BG, Oliveira M, Asahchop EL, Moisi D, Wainberg MA. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrobial Agents and Chemotherapy. 53: 708-15. PMID 19064892 DOI: 10.1128/Aac.01109-08  0.613
2008 Wainberg MA. HIV transmission should be decriminalized: HIV prevention programs depend on it Retrovirology. 5. PMID 19046412 DOI: 10.1186/1742-4690-5-108  0.502
2008 Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. Journal of Medical Virology. 80: 2053-63. PMID 19040279 DOI: 10.1002/Jmv.21329  0.504
2008 Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries. Journal of the International Aids Society. 11: 2. PMID 19014657 DOI: 10.1186/1758-2652-11-2  0.8
2008 Wainberg MA, Jeang KT. 25 years of HIV-1 research - Progress and perspectives Bmc Medicine. 6. PMID 18976462 DOI: 10.1186/1741-7015-6-31  0.42
2008 Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. The impact of the journalist-to-journalist program on worldwide HIV awareness. Aids (London, England). 22: 1687-8. PMID 18670235 DOI: 10.1097/Qad.0B013E328308De21  0.805
2008 Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. Whither or wither microbicides? Science (New York, N.Y.). 321: 532-4. PMID 18653884 DOI: 10.1126/Science.1160355  0.338
2008 Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proceedings of the National Academy of Sciences of the United States of America. 105: 9835-40. PMID 18606986 DOI: 10.1073/Pnas.0711813105  0.413
2008 Ntemgwa M, Gill MJ, Brenner BG, Moisi D, Wainberg MA. Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. Aids Research and Human Retroviruses. 24: 995-1002. PMID 18593348 DOI: 10.1089/Aid.2008.0064  0.507
2008 Quan Y, Brenner BG, Dascal A, Wainberg MA. Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report. Retrovirology. 5: 43. PMID 18513421 DOI: 10.1186/1742-4690-5-43  0.571
2008 Ntemgwa M, Toni TD, Brenner BG, Routy JP, Moisi D, Oliveira M, Wainberg MA. Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada. Aids Research and Human Retroviruses. 24: 655-9. PMID 18366312 DOI: 10.1089/Aid.2007.0282  0.489
2008 Braitstein P, Boulle A, Nash D, Brinkhof MWG, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinipour M, May M, Egger M, Bangsberg DR, Low N, ... ... Wainberg M, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: Findings from a multicenter collaboration Journal of Women's Health. 17: 47-55. PMID 18240981 DOI: 10.1089/Jwh.2007.0353  0.443
2008 Martinez-Cajas JL, Wainberg MA. Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs. 68: 43-72. PMID 18081372 DOI: 10.2165/00003495-200868010-00004  0.483
2008 Coutsinos D, Sloan R, Wainberg MA. Antiviral drug development: progress and pitfalls Future Virology. 3: 529-532. DOI: 10.2217/17460794.3.6.529  0.48
2008 Brenner B, Toni Td, Roger M, Routy J, Moisi D, Wainberg M. O114 NNRTI mutations are efficiently transmitted within clusters of new HIV infections Journal of the International Aids Society. 11: O4. DOI: 10.1186/1758-2652-11-S1-O4  0.448
2008 Blower S, Wilson DP, Coplan PM, Wainberg MA. Reply to Heise and Philpott: The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics Proceedings of the National Academy of Sciences of the United States of America. 105: E74. DOI: 10.1073/Pnas.0808272105  0.493
2008 Wainberg MA, Petrella M. Development and Transmission of HIV Drug Resistance Global Hiv/Aids Medicine. 149-159. DOI: 10.1016/B978-1-4160-2882-6.50018-6  0.445
2007 Wainberg MA, Clotet B. Immunologic response to protease inhibitor-based highly active antiretroviral therapy: A review Aids Patient Care and Stds. 21: 609-620. PMID 17919088 DOI: 10.1089/Apc.2006.0176  0.324
2007 Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine Antimicrobial Agents and Chemotherapy. 51: 3861-3869. PMID 17724152 DOI: 10.1128/Aac.00646-07  0.407
2007 Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Research. 76: 203-21. PMID 17673305 DOI: 10.1016/J.Antiviral.2007.06.010  0.546
2007 Dandache S, Sévigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1 Antimicrobial Agents and Chemotherapy. 51: 4036-4043. PMID 17638694 DOI: 10.1128/Aac.00149-07  0.594
2007 Whitney JB, Wainberg MA. Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome. Retrovirology. 4: 44. PMID 17608929 DOI: 10.1186/1742-4690-4-44  0.676
2007 Frankel FA, Coutsinos D, Xu H, Wainberg MA. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. Antiviral Chemistry & Chemotherapy. 18: 93-101. PMID 17542154 DOI: 10.1177/095632020701800205  0.482
2007 Wainberg MA, Cahn P, Bethell RC, Sawyer J, Cox S. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antiviral Chemistry & Chemotherapy. 18: 61-70. PMID 17542150 DOI: 10.1177/095632020701800201  0.555
2007 Invernizzi CF, Xie B, Frankel FA, Feldhammer M, Roy BB, Richard S, Wainberg MA. Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function. Aids (London, England). 21: 795-805. PMID 17415034 DOI: 10.1097/Qad.0B013E32803277Ae  0.471
2007 Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. Aids (London, England). 21: 665-75. PMID 17413687 DOI: 10.1097/Qad.0B013E3280187505  0.578
2007 Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA, et al. High rates of forward transmission events after acute/early HIV-1 infection Journal of Infectious Diseases. 195: 951-959. PMID 17330784 DOI: 10.1086/512088  0.518
2007 Gayle H, Wainberg MA. Impact of the 16th International Conference on AIDS: Can these conferences lead to policy change? Retrovirology. 4. PMID 17288591 DOI: 10.1186/1742-4690-4-13  0.376
2007 Gatignol A, Dubuisson J, Wainberg MA, Cohen EA, Darlix JL. New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu. Retrovirology. 4: 8. PMID 17270043 DOI: 10.1186/1742-4690-4-8  0.458
2007 Xie B, Invernizzi CF, Richard S, Wainberg MA. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. Journal of Virology. 81: 4226-34. PMID 17267505 DOI: 10.1128/Jvi.01888-06  0.509
2007 Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Brenner BG, Wainberg MA. Molecular characterization of the development of the K65R and M184V drug resistance mutations in Subtype C HIV-1s Clinical & Investigative Medicine. 30: 78. DOI: 10.25011/Cim.V30I4.2847  0.496
2007 Wainberg MA, Martinez-Cajas JL, Brenner BG. Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance Future Hiv Therapy. 1: 291-313. DOI: 10.2217/17469600.1.3.291  0.443
2007 Wainberg MA. Introducing Future HIV Therapy Future Hiv Therapy. 1: 1-2. DOI: 10.2217/17469600.1.1.1  0.489
2006 Whitney JB, Wainberg MA. Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239. Retrovirology. 3: 96. PMID 17184529 DOI: 10.1186/1742-4690-3-96  0.637
2006 Invernizzi CF, Xie B, Richard S, Wainberg MA. PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology. 3: 93. PMID 17176473 DOI: 10.1186/1742-4690-3-93  0.481
2006 Wainberg MA. The need to promote public health in the field of illicit drug use Cmaj. 175: 1395-1396. PMID 17116908 DOI: 10.1503/Cmaj.061404  0.474
2006 Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrobial Agents and Chemotherapy. 51: 604-10. PMID 17116674 DOI: 10.1128/Aac.00870-06  0.608
2006 Derdelinckx I, Wainberg MA, Lange JM, Hill A, Halima Y, Boucher CA. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. Plos Medicine. 3: e454. PMID 17090213 DOI: 10.1371/Journal.Pmed.0030454  0.531
2006 Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrobial Agents and Chemotherapy. 50: 4182-5. PMID 17015626 DOI: 10.1128/Aac.00714-06  0.431
2006 Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: Moving forward with caution Journal of Infectious Diseases. 194: 874-876. PMID 16960773 DOI: 10.1086/507314  0.507
2006 Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. Aids (London, England). 20: F9-13. PMID 16816549 DOI: 10.1097/01.Aids.0000232228.88511.0B  0.544
2006 Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Research. 71: 343-50. PMID 16787667 DOI: 10.1016/J.Antiviral.2006.05.013  0.57
2006 Turner D, Wainberg MA. HIV transmission and primary drug resistance Aids Reviews. 8: 17-23. PMID 16736948  0.479
2006 Solis M, Wilkinson P, Romieu R, Hernandez E, Wainberg MA, Hiscott J. Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells. Virology. 352: 86-99. PMID 16730773 DOI: 10.1016/J.Virol.2006.04.010  0.464
2006 Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M, Wainberg MA. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrobial Agents and Chemotherapy. 50: 2210-3. PMID 16723586 DOI: 10.1128/Aac.01447-05  0.461
2006 Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP. Effects of drug resistance on viral load in patients failing antiretroviral therapy Journal of Medical Virology. 78: 608-613. PMID 16555280 DOI: 10.1002/Jmv.20582  0.44
2006 Wainberg MA. The XVI International Conference on AIDS: The place to be! Retrovirology. 3. PMID 16457720 DOI: 10.1186/1742-4690-3-9  0.456
2006 Götte M, Wainberg MA. Significance of the L74V mutation in HIV-1 reverse transcriptase Future Virology. 1: 493-500. DOI: 10.2217/17460794.1.4.493  0.496
2006 Richards D, Alibek K, Katze MG, Wainberg MA, Webby RJ. Controversies in 21st century virology Future Virology. 1: 263-268. DOI: 10.2217/17460794.1.3.263  0.364
2006 Wainberg MA, Doualla-Bell F, Gaolatte T, Mine M, Essex M, Brenner B. HIV-1 subtype C viruses rapidly develop K65R Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-S4  0.53
2005 Turner D, Brenner B, Moisi D, Liang C, Wainberg MA. Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs. Journal of the International Aids Society. 7: 69. PMID 19825125 DOI: 10.1186/1758-2652-7-1-69  0.434
2005 Turner D, Brenner B, Mosis D, Liang C, Wainberg MA. Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs. Medgenmed : Medscape General Medicine. 7: 69. PMID 16369374  0.322
2005 Grant RM, Buchbinder S, Cates W, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, ... ... Wainberg MA, et al. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (New York, N.Y.). 309: 2170-1. PMID 16195446 DOI: 10.1126/Science.1116204  0.426
2005 Guo X, Roy BB, Hu J, Roldan A, Wainberg MA, Liang C. The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA. Virology. 343: 190-200. PMID 16183096 DOI: 10.1016/J.Virol.2005.08.031  0.474
2005 Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. Journal of Virology. 79: 9180-91. PMID 15994812 DOI: 10.1128/Jvi.79.14.9180-9191.2005  0.501
2005 Frankel FA, Marchand B, Turner D, Götte M, Wainberg MA. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 49: 2657-64. PMID 15980333 DOI: 10.1128/Aac.49.7.2657-2664.2005  0.543
2005 Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 41: 92-9. PMID 15937768 DOI: 10.1086/430706  0.367
2005 Wainberg MA, Brenner BG, Turner D. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 49: 1671-8. PMID 15855480 DOI: 10.1128/Aac.49.5.1671-1678.2005  0.558
2005 Roldan A, Warren OU, Russell RS, Liang C, Wainberg MA. A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription. The Journal of Biological Chemistry. 280: 17488-96. PMID 15731102 DOI: 10.1074/Jbc.M501310200  0.51
2005 Wainberg MA. Generic HIV drugs - Enlightened policy for global health New England Journal of Medicine. 352: 747-750. PMID 15728804 DOI: 10.1056/Nejmp048356  0.456
2005 Guo X, Roldan A, Hu J, Wainberg MA, Liang C. Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. Journal of Virology. 79: 1803-12. PMID 15650204 DOI: 10.1128/Jvi.79.3.1803-1812.2005  0.376
2005 Boulanger MC, Liang C, Russell RS, Lin R, Bedford MT, Wainberg MA, Richard S. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. Journal of Virology. 79: 124-31. PMID 15596808 DOI: 10.1128/Jvi.79.1.124-131.2005  0.56
2005 Turner D, Roldan A, Brenner B, Moisi D, Routy JP, Wainberg MA. Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. Antiviral Chemistry & Chemotherapy. 15: 255-9. PMID 15535047 DOI: 10.1177/095632020401500504  0.547
2005 Wainberg MA. Retrovirology. 2: S122. DOI: 10.1186/1742-4690-2-S1-S122  0.578
2004 Wainberg MA, Lange JM, Gayle HD, McClure C, Sterritt C. eJIAS: The Journal of HIV/AIDS Science and Medicine in the Developing World. Journal of the International Aids Society. 6: 56. PMID 19825121 DOI: 10.1186/1758-2652-6-3-56  0.464
2004 Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, Rouleau D, Tremblay CL, Côté P, Baril JG, Remis RS, Sékaly RP, Wainberg MA. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. Aids (London, England). 18: 2305-12. PMID 15577543 DOI: 10.1097/00002030-200411190-00011  0.493
2004 Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, Wainberg MA. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1627-31. PMID 15577421 DOI: 10.1097/00126334-200412150-00017  0.558
2004 Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG, Wainberg MA. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrobial Agents and Chemotherapy. 48: 4189-94. PMID 15504840 DOI: 10.1128/Aac.48.11.4189-4194.2004  0.413
2004 Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness Expert Review of Anti-Infective Therapy. 2: 147-151. PMID 15482179  0.504
2004 Doualla-Bell F, Turner D, Loemba H, Petrella M, Brenner B, Wainberg MA. [HIV drug resistance and optimization of antiviral treatment in resource-poor countries]. Medecine Sciences : M/S. 20: 882-6. PMID 15461965 DOI: 10.1051/Medsci/20042010882  0.825
2004 Doualla-Bell F, Gaseitsiwe S, Ndungú T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Tendani G, Avalos A, Wester W, Bussmann H, Cardiello P, Marlink R, Moffat H, Thior I, ... Wainberg MA, et al. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antiviral Chemistry & Chemotherapy. 15: 189-200. PMID 15457680 DOI: 10.1177/095632020401500402  0.525
2004 Russell RS, Liang C, Wainberg MA. Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology. 1: 23. PMID 15345057 DOI: 10.1186/1742-4690-1-23  0.407
2004 Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance Aids. 18. PMID 15322487 DOI: 10.1097/00002030-200406003-00012  0.572
2004 Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options Journal of Acquired Immune Deficiency Syndromes. 37. PMID 15319668 DOI: 10.1097/01.Qai.0000137005.63376.6E  0.386
2004 Wainberg MA. The emergence of HIV resistance and new antiretrovirals: Are we winning? Drug Resistance Updates. 7: 163-167. PMID 15296858 DOI: 10.1016/J.Drup.2004.06.001  0.438
2004 Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. Aids (London, England). 18: 1653-60. PMID 15280776 DOI: 10.1097/01.Aids.0000131377.28694.04  0.469
2004 Turner D, Brenner B, Moisi D, Detorio M, Cesaire R, Kurimura T, Mori H, Essex M, Maayan S, Wainberg MA. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 48: 2993-8. PMID 15273111 DOI: 10.1128/Aac.48.8.2993-2998.2004  0.465
2004 Turner D, Schapiro JM, Brenner BG, Wainberg MA. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients Antiviral Therapy. 9: 301-314. PMID 15259893  0.437
2004 Roldan A, Russell RS, Marchand B, Götte M, Liang C, Wainberg MA. In vitro identification and characterization of an early complex linking HIV-1 genomic RNA recognition and Pr55Gag multimerization. The Journal of Biological Chemistry. 279: 39886-94. PMID 15247214 DOI: 10.1074/Jbc.M405632200  0.468
2004 Wainberg MA, Brenner BG, Daar E, Gertner JM, Olivier C, Kenley S. Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 48: 2337-40. PMID 15155249 DOI: 10.1128/Aac.48.6.2337-2340.2004  0.421
2004 Spira SC, Wainberg MA. Jewish religious ethics mandate access to antiretroviral drugs in developing countries Journal of the International Association of Physicians in Aids Care. 3: 7-11. PMID 15112418 DOI: 10.1177/154510970400300102  0.453
2004 Petrella M, Montaner J, Batist G, Wainberg MA. The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Investigation. 22: 149-60. PMID 15069773 DOI: 10.1081/Cnv-120027590  0.473
2004 Wainberg MA. Is there any hope for AIDS? Clinical and Investigative Medicine. 27: 51-58. PMID 15061586  0.455
2004 Liang C, Hu J, Russell RS, Kameoka M, Wainberg MA. Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells. Aids Research and Human Retroviruses. 20: 203-11. PMID 15018708 DOI: 10.1089/088922204773004923  0.426
2004 Xie B, Calabro V, Wainberg MA, Frankel AD. Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system. Journal of Virology. 78: 1456-63. PMID 14722301 DOI: 10.1128/Jvi.78.3.1456-1463.2004  0.494
2004 Russell RS, Roldan A, Detorio M, Hu J, Wainberg MA, Liang C. Effects of a single amino acid substitution within the p2 region of human immunodeficiency virus type 1 on packaging of spliced viral RNA. Journal of Virology. 77: 12986-95. PMID 14645555 DOI: 10.1128/Jvi.77.24.12986-12995.2003  0.421
2004 Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clinical and Diagnostic Laboratory Immunology. 10: 979-81. PMID 14607855 DOI: 10.1128/Cdli.10.6.979-981.2003  0.556
2004 Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. Journal of the International Association of Physicians in Aids Care (Chicago, Ill. : 2002). 2: 102-5. PMID 14556428 DOI: 10.1177/154510970300200302  0.391
2004 Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. Journal of the International Association of Physicians in Aids Care (Chicago, Ill. : 2002). 2: 102-5. PMID 14556428 DOI: 10.1177/154510970300200302  0.391
2004 Hsu RK, Wainberg MA. Do New Protease Inhibitors Offer Improved Sequencing Options? Issues of PI Resistance and Sequencing Journal of Acquired Immune Deficiency Syndromes. 35.  0.315
2003 Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antiviral Therapy. 8: 489-506. PMID 14760883  0.33
2003 Turner D, Brenner B, Wainberg MA. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. The Journal of Antimicrobial Chemotherapy. 53: 53-7. PMID 14645322 DOI: 10.1093/Jac/Dkh009  0.59
2003 Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, Wainberg MA. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. Aids Research and Human Retroviruses. 19: 743-53. PMID 14585205 DOI: 10.1089/088922203769232548  0.429
2003 Diallo K, Götte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 47: 3377-83. PMID 14576091 DOI: 10.1128/Aac.47.11.3377-3383.2003  0.597
2003 Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors Journal of Acquired Immune Deficiency Syndromes. 34. PMID 14562852 DOI: 10.1097/00126334-200309011-00002  0.558
2003 Rong L, Russell RS, Hu J, Laughrea M, Wainberg MA, Liang C. Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1. Virology. 314: 221-8. PMID 14517075 DOI: 10.1016/S0042-6822(03)00405-7  0.628
2003 Diallo K, Marchand B, Wei X, Cellai L, Götte M, Wainberg MA. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. Journal of Virology. 77: 8621-32. PMID 12885880 DOI: 10.1128/Jvi.77.16.8621-8632.2003  0.528
2003 Wei X, Liang C, Götte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology. 311: 202-12. PMID 12832217 DOI: 10.1016/S0042-6822(03)00173-9  0.524
2003 Diallo K, Brenner B, Oliveira M, Moisi D, Detorio M, Götte M, Wainberg MA. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrobial Agents and Chemotherapy. 47: 2376-9. PMID 12821504 DOI: 10.1128/Aac.47.7.2376-2379.2003  0.534
2003 Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Safety. 26: 605-24. PMID 12814330 DOI: 10.2165/00002018-200326090-00002  0.54
2003 Klein MB, Campeol N, Lalonde RG, Brenner B, Wainberg MA. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. Aids (London, England). 17: 1001-8. PMID 12700449 DOI: 10.1097/01.Aids.0000060357.78202.25  0.524
2003 Guo X, Kameoka M, Wei X, Roques B, Gotte M, Liang C, Wainberg MA. Suppression of an intrinsic strand transfer activity of HIV-1 Tat protein by its second-exon sequences. Virology. 307: 154-63. PMID 12667823 DOI: 10.1016/S0042-6822(02)00068-5  0.508
2003 Youle M, Wainberg MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? [4] Aids. 17: 937-938. PMID 12660549 DOI: 10.1097/00002030-200304110-00027  0.418
2003 Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. The Journal of Antimicrobial Chemotherapy. 51: 229-40. PMID 12562686 DOI: 10.1093/Jac/Dkg079  0.844
2003 Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrobial Agents and Chemotherapy. 47: 747-54. PMID 12543687 DOI: 10.1128/Aac.47.2.747-754.2003  0.554
2003 Xie B, Wainberg MA, Frankel AD. Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions. Journal of Virology. 77: 1984-91. PMID 12525632 DOI: 10.1128/Jvi.77.3.1984-1991.2003  0.512
2003 Liang C, Hu J, Whitney JB, Kleiman L, Wainberg MA. A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1. Journal of Virology. 77: 1772-83. PMID 12525611 DOI: 10.1128/Jvi.77.3.1772-1783.2003  0.707
2003 Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors Aids. 17. PMID 12478089 DOI: 10.1097/00002030-200301030-00001  0.467
2003 Russell RS, Hu J, Bériault V, Mouland AJ, Laughrea M, Kleiman L, Wainberg MA, Liang C. Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA. Journal of Virology. 77: 84-96. PMID 12477813 DOI: 10.1128/Jvi.77.1.84-96.2003  0.349
2003 McLellan N, Wei X, Marchand B, Wainberg MA, Götte M. Nonradioactive detection of retroviral-associated RNase H activity in a microplate-based, high-throughput format. Biotechniques. 33: 424-9. PMID 12188196 DOI: 10.2144/02332Ht03  0.448
2003 Wainberg MA. HIV DART 2002: Frontiers in drug development for antiretroviral therapies: 15-19 December 2002, Naples, FL, USA Idrugs. 6: 110-113.  0.418
2002 Petrella M, Wainberg MA. Might the M184V substitution in HIV-1 RT confer clinical benefit? Aids Reviews. 4: 224-232. PMID 12555696  0.369
2002 Russell RS, Hu J, Laughrea M, Wainberg MA, Liang C. Deficient dimerization of human immunodeficiency virus type 1 RNA caused by mutations of the u5 RNA sequences. Virology. 303: 152-63. PMID 12482667 DOI: 10.1006/Viro.2002.1592  0.372
2002 Hogg R, Cahn P, Katabira ET, Lange J, Samuel NM, O'Shaughnessy M, Vella S, Wainberg MA, Montaner J. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (London, England). 360: 1710-1. PMID 12480418 DOI: 10.1016/S0140-6736(02)11722-3  0.474
2002 Wei X, Liang C, Götte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. Aids (London, England). 16: 2391-8. PMID 12461412 DOI: 10.1097/00002030-200212060-00003  0.593
2002 Liang C, Hu J, Russell RS, Wainberg MA. Translation of Pr55(gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner. Aids Research and Human Retroviruses. 18: 1117-26. PMID 12396450 DOI: 10.1089/088922202320567851  0.429
2002 Liang C, Hu J, Russell RS, Roldan A, Kleiman L, Wainberg MA. Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. Journal of Virology. 76: 11729-37. PMID 12388733 DOI: 10.1128/Jvi.76.22.11729-11737.2002  0.358
2002 Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: Can we overcome? Expert Opinion On Biological Therapy. 2: 751-761. PMID 12387674 DOI: 10.1517/14712598.2.7.751  0.568
2002 Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Essex M, Wainberg MA. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Research. 56: 129-42. PMID 12367719 DOI: 10.1016/S0166-3542(02)00100-6  0.839
2002 Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Essex M, Wainberg MA. Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Antiviral Therapy. 7: 141-8. PMID 12212926  0.823
2002 Borkow G, Salomon H, Wainberg MA, Parniak MA. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. Aids Research and Human Retroviruses. 18: 711-4. PMID 12167278 DOI: 10.1089/088922202760072339  0.545
2002 Whitney JB, Oliveira M, Detorio M, Guan Y, Wainberg MA. The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus. Journal of Virology. 76: 8958-62. PMID 12163615 DOI: 10.1128/Jvi.76.17.8958-8962.2002  0.686
2002 Diallo K, Oliveira M, Moisi D, Brenner B, Wainberg MA, Götte M. Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 46: 2254-6. PMID 12069983 DOI: 10.1128/Aac.46.7.2254-2256.2002  0.571
2002 Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Wainberg MA. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrobial Agents and Chemotherapy. 46: 2087-94. PMID 12069959 DOI: 10.1128/Aac.46.7.2087-2094.2002  0.802
2002 Roof P, Ricci M, Genin P, Montano MA, Essex M, Wainberg MA, Gatignol A, Hiscott J. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology. 296: 77-83. PMID 12036319 DOI: 10.1006/Viro.2001.1397  0.519
2002 Petrella M, Brenner B, Loemba H, Wainberg MA. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 4: 339-46. PMID 12030782 DOI: 10.1054/Drup.2002.0235  0.819
2002 Van Rompay KK, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC, North TW. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. Journal of Virology. 76: 6083-92. PMID 12021341 DOI: 10.1128/Jvi.76.12.6083-6092.2002  0.436
2002 Liang C, Wainberg MA. The role of Tat in HIV-1 replication: An activator and/or a suppressor? Aids Reviews. 4: 41-49. PMID 11998784  0.401
2002 Khorchid A, Halwani R, Wainberg MA, Kleiman L. Role of RNA in facilitating Gag/Gag-Pol interaction. Journal of Virology. 76: 4131-7. PMID 11907255 DOI: 10.1128/Jvi.76.8.4131-4137.2002  0.417
2002 Kameoka M, Morgan M, Binette M, Russell RS, Rong L, Guo X, Mouland A, Kleiman L, Liang C, Wainberg MA. The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. Journal of Virology. 76: 3637-45. PMID 11907203 DOI: 10.1128/Jvi.76.8.3637-3645.2002  0.668
2002 Brulé F, Marquet R, Rong L, Wainberg MA, Roques BP, Le Grice SF, Ehresmann B, Ehresmann C. Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex. Rna (New York, N.Y.). 8: 8-15. PMID 11873759 DOI: 10.1017/S1355838202010981  0.606
2002 Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. Journal of Virology. 76: 1753-61. PMID 11799170 DOI: 10.1128/Jvi.76.4.1753-1761.2002  0.452
2002 Whitney JB, Wainberg MA. Isoniazid, the frontline of resistance in mycobacterium tuberculosis McGill Journal of Medicine. 6: 114-123.  0.57
2001 Guan Y, Diallo K, Whitney JB, Liang C, Wainberg MA. An intact U5-leader stem is important for efficient replication of simian immunodeficiency virus. Journal of Virology. 75: 11924-9. PMID 11689678 DOI: 10.1128/Jvi.75.23.11924-11929.2001  0.663
2001 Guan Y, Diallo K, Detorio M, Whitney JB, Liang C, Wainberg MA. Partial restoration of replication of simian immunodeficiency virus by point mutations in either the dimerization initiation site (DIS) or Gag region after deletion mutagenesis within the DIS. Journal of Virology. 75: 11920-3. PMID 11689677 DOI: 10.1128/Jvi.75.23.11920-11923.2001  0.665
2001 Rong L, Liang C, Hsu M, Guo X, Roques BP, Wainberg MA. HIV-1 nucleocapsid protein and the secondary structure of the binary complex formed between tRNA(Lys.3) and viral RNA template play different roles during initiation of (-) strand DNA reverse transcription. The Journal of Biological Chemistry. 276: 47725-32. PMID 11602578 DOI: 10.1074/Jbc.M105124200  0.671
2001 Shen N, Jetté L, Wainberg MA, Laughrea M. Role of stem B, loop B, and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization. Journal of Virology. 75: 10543-9. PMID 11581429 DOI: 10.1128/Jvi.75.21.10543-10549.2001  0.376
2001 Rong L, Russell RS, Hu J, Guan Y, Kleiman L, Liang C, Wainberg MA. Hydrophobic amino acids in the human immunodeficiency virus type 1 p2 and nucleocapsid proteins can contribute to the rescue of deleted viral RNA packaging signals. Journal of Virology. 75: 7230-43. PMID 11461996 DOI: 10.1128/Jvi.75.16.7230-7243.2001  0.603
2001 Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. Aids (London, England). 15: 1269-74. PMID 11426071 DOI: 10.1097/00002030-200107060-00008  0.348
2001 Guan Y, Whitney JB, Detorio M, Wainberg MA. Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. Journal of Virology. 75: 4056-67. PMID 11287555 DOI: 10.1128/Jvi.75.9.4056-4067.2001  0.653
2001 Guan Y, Whitney JB, Liang C, Wainberg MA. Novel, live attenuated simian immunodeficiency virus constructs containing major deletions in leader RNA sequences. Journal of Virology. 75: 2776-85. PMID 11222701 DOI: 10.1128/Jvi.75.6.2776-2785.2001  0.672
2001 Kameoka M, Rong L, Götte M, Liang C, Russell RS, Wainberg MA. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. Journal of Virology. 75: 2675-83. PMID 11222691 DOI: 10.1128/Jvi.75.6.2675-2683.2001  0.668
2001 Laughrea M, Shen N, Jetté L, Darlix JL, Kleiman L, Wainberg MA. Role of distal zinc finger of nucleocapsid protein in genomic RNA dimerization of human immunodeficiency virus type 1; no role for the palindrome crowning the R-U5 hairpin. Virology. 281: 109-16. PMID 11222101 DOI: 10.1006/Viro.2000.0778  0.382
2001 Diallo K, Loemba H, Oliveira M, Mavoungou DD, Wainberg MA. Inhibition of human immunodeficiency virus type-1 (HIV-1) replication by immunor (IM28), a new analog of dehydroepiandrosterone. Nucleosides, Nucleotides & Nucleic Acids. 19: 2019-24. PMID 11200288 DOI: 10.1080/15257770008045475  0.448
2001 Wainberg MA, Youle M. Can we protect high-risk populations against HIV infection through use of antiviral drugs? A proposal for once-daily pre-exposure prophylaxis of HIV disease International Antiviral News. 9: 184-185.  0.416
2000 Götte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 3: 30-38. PMID 11498363 DOI: 10.1054/Drup.2000.0126  0.535
2000 Richard N, Salomon H, Oliveira M, Rando R, Mansour T, Gu Z, Wainberg MA. Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC. Antiviral Chemistry & Chemotherapy. 11: 359-65. PMID 11227993 DOI: 10.1177/095632020001100602  0.515
2000 Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection Annals of the New York Academy of Sciences. 918: 9-15. PMID 11131739 DOI: 10.1111/J.1749-6632.2000.Tb05467.X  0.552
2000 Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly RP, Conway B, Routy JP. Resistance to antiretroviral drugs in patients with primary HIV-1 infection International Journal of Antimicrobial Agents. 16: 429-434. PMID 11118853 DOI: 10.1016/S0924-8579(00)00270-3  0.537
2000 Götte M, Kameoka M, McLellan N, Cellai L, Wainberg MA. Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription. The Journal of Biological Chemistry. 276: 6711-9. PMID 11096104 DOI: 10.1074/Jbc.M009097200  0.447
2000 Cen S, Khorchid A, Gabor J, Rong L, Wainberg MA, Kleiman L. Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the initiation step of reverse transcription in human immunodeficiency virus type 1. Journal of Virology. 74: 10796-800. PMID 11044125 DOI: 10.1128/Jvi.74.22.10796-10800.2000  0.604
2000 Guan Y, Whitney JB, Diallo K, Wainberg MA. Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus. Journal of Virology. 74: 8854-60. PMID 10982327 DOI: 10.1128/Jvi.74.19.8854-8860.2000  0.703
2000 Wei X, Götte M, Wainberg MA. Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers Nucleic Acids Research. 28: 3065-3074. PMID 10931921 DOI: 10.1093/Nar/28.16.3065  0.368
2000 Liang C, Rong L, Russell RS, Wainberg MA. Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene. Journal of Virology. 74: 6251-61. PMID 10864634 DOI: 10.1128/Jvi.74.14.6251-6261.2000  0.611
2000 Khorchid A, Javanbakht H, Wise S, Halwani R, Parniak MA, Wainberg MA, Kleiman L. Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1. Journal of Molecular Biology. 299: 17-26. PMID 10860720 DOI: 10.1006/Jmbi.2000.3709  0.504
2000 Shen N, Jetté L, Liang C, Wainberg MA, Laughrea M. Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging. Journal of Virology. 74: 5729-35. PMID 10823883 DOI: 10.1128/Jvi.74.12.5729-5735.2000  0.408
2000 Richard N, Salomon H, Rando R, Mansour T, Bowlin TL, Wainberg MA. Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine. Antimicrobial Agents and Chemotherapy. 44: 1127-31. PMID 10770740 DOI: 10.1128/Aac.44.5.1127-1131.2000  0.538
2000 Hsu M, Rong L, de Rocquigny H, Roques BP, Wainberg MA. The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions. Nucleic Acids Research. 28: 1724-9. PMID 10734191 DOI: 10.1093/Nar/28.8.1724  0.658
2000 Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. Journal of Virology. 74: 3579-85. PMID 10729133 DOI: 10.1128/Jvi.74.8.3579-3585.2000  0.44
2000 Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. Aids (London, England). 14: F17-23. PMID 10708278 DOI: 10.1097/00002030-200001280-00003  0.56
1999 DeLuca C, Kwon H, Lin R, Wainberg M, Hiscott J. NF-kappaB activation and HIV-1 induced apoptosis. Cytokine & Growth Factor Reviews. 10: 235-53. PMID 10647779 DOI: 10.1016/S1359-6101(99)00015-5  0.489
1999 Génin P, Mamane Y, Kwon H, LePage C, Wainberg MA, Hiscott J. Differential regulation of CC chemokine gene expression in human immunodeficiency virus-infected myeloid cells. Virology. 261: 205-15. PMID 10497106 DOI: 10.1006/Viro.1999.9852  0.521
1999 Machado J, Salomon H, Oliveira M, Tsoukas C, Krayevsky AA, Wainberg MA. Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT. Nucleosides & Nucleotides. 18: 901-6. PMID 10432707 DOI: 10.1080/15257779908041597  0.423
1999 Gu Z, Wainberg MA, Nguyen-Ba P, L'Heureux L, de Muys JM, Rando RF. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. Nucleosides & Nucleotides. 18: 891-2. PMID 10432704 DOI: 10.1080/15257779908041594  0.544
1999 Richard N, Salomon H, Oliveira M, Rando R, Wainberg MA. Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine. Nucleosides & Nucleotides. 18: 773-8. PMID 10432679 DOI: 10.1080/15257779908041564  0.448
1999 Liang C, Rong L, Quan Y, Laughrea M, Kleiman L, Wainberg MA. Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site. Journal of Virology. 73: 7014-20. PMID 10400801 DOI: 10.1128/Jvi.73.8.7014-7020.1999  0.634
1999 Quan Y, Rong L, Liang C, Wainberg MA. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. Journal of Virology. 73: 6700-7. PMID 10400767 DOI: 10.1128/Jvi.73.8.6700-6707.1999  0.67
1999 Germinario RJ, Colby-Germinario SP, Acel A, Chandok R, Davison K, Mak J, Kleiman L, Faust E, Wainberg MA. Effect of insulin-like growth factor I on HIV type 1 long terminal repeat-driven chloramphenicol acetyltransferase expression. Aids Research and Human Retroviruses. 15: 829-36. PMID 10381171 DOI: 10.1089/088922299310737  0.386
1999 Wainberg MA. A new source of resistance to HIV drugs Journal of the American Medical Association. 281: 2169-2170. PMID 10376549 DOI: 10.1001/Jama.281.23.2169  0.512
1999 Wainberg MA. South Africa must admit that HIV/AIDS is its greatest enemy [13] British Medical Journal. 318: 1700. PMID 10373193  0.423
1999 Liang C, Rong L, Cherry E, Kleiman L, Laughrea M, Wainberg MA. Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. Journal of Virology. 73: 6147-51. PMID 10364374 DOI: 10.1128/Jvi.73.7.6147-6151.1999  0.656
1999 Rübsamen-Waigmann H, Huguenel E, Shah A, Paessens A, Ruoff HJ, von Briesen H, Immelmann A, Dietrich U, Wainberg MA. Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro. Antiviral Research. 42: 15-24. PMID 10333139 DOI: 10.1016/S0166-3542(99)00010-8  0.463
1999 Götte M, Li X, Wainberg MA. HIV-1 reverse transcription: A brief overview focused on structure- function relationships among molecules involved in initiation of the reaction Archives of Biochemistry and Biophysics. 365: 199-210. PMID 10328813 DOI: 10.1006/Abbi.1999.1209  0.434
1999 Hsu M, Cherry E, Quan Y, Richard N, Kleiman L, Wainberg MA. Effect of mutations in NC7 on endogenous reverse transcription in HIV-1. Leukemia. S113-5. PMID 10232383 DOI: 10.1038/Sj.Leu.2401325  0.526
1999 Brenner BG, Wainberg MA. Heat shock protein-based therapeutic strategies against human immunodeficiency virus type I infection Infectious Diseases in Obstetrics and Gynecology. 7: 80-90. PMID 10231014  0.392
1999 Kang CY, Luo L, Wainberg MA, Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biological Chemistry. 380: 353-64. PMID 10223338 DOI: 10.1515/BC.1999.047  0.457
1999 Cen S, Huang Y, Khorchid A, Darlix JL, Wainberg MA, Kleiman L. The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA. Journal of Virology. 73: 4485-8. PMID 10196352 DOI: 10.1128/Jvi.73.5.4485-4488.1999  0.536
1999 Götte M, Maier G, Onori AM, Cellai L, Wainberg MA, Heumann H. Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. The Journal of Biological Chemistry. 274: 11159-69. PMID 10196201 DOI: 10.1074/Jbc.274.16.11159  0.337
1999 Borkow G, Arion D, Wainberg MA, Parniak MA. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 43: 259-63. PMID 9925515 DOI: 10.1128/Aac.43.2.259  0.574
1999 Laughrea M, Shen N, Jetté L, Wainberg MA. Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization. Biochemistry. 38: 226-34. PMID 9890902 DOI: 10.1021/Bi981728J  0.566
1999 Quan Y, Liang C, Inouye P, Wainberg MA. Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. Nucleic Acids Research. 26: 5692-8. PMID 9838001 DOI: 10.1093/Nar/26.24.5692  0.465
1999 Cen S, Huang Y, Khorchid A, Darlix J, Wainberg MA, Kleiman L. The Role of Pr55 gag in the Annealing of tRNA3 Lys to Human Immunodeficiency Virus Type 1 Genomic RNA Journal of Virology. 73: 4485-4488. DOI: 10.1128/jvi.73.5.4485-4488.1999  0.429
1999 de Muys J, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA, Rando RF. Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2′-Deoxy-3′-Oxa-4′-Thiocytidine Antimicrobial Agents and Chemotherapy. 43: 1835-1844. DOI: 10.1128/Aac.43.8.1835  0.56
1999 Borkow G, Arion D, Wainberg MA, Parniak MA. The Thiocarboxanilide Nonnucleoside Inhibitor UC781 Restores Antiviral Activity of 3′-Azido-3′-Deoxythymidine (AZT) against AZT-Resistant Human Immunodeficiency Virus Type 1 Antimicrobial Agents and Chemotherapy. 43: 259-263. DOI: 10.1128/aac.43.2.259  0.484
1999 Gu Z, Wainberg MA, Nguyen-Ba N, L’Heureux L, de Muys J, Bowlin TL, Rando RF. Mechanism of Action and In Vitro Activity of 1′,3′-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Antimicrobial Agents and Chemotherapy. 43: 2376-2382. DOI: 10.1128/Aac.43.10.2376  0.614
1999 Wainberg MA. Hope and despair: New drug development versus transmission of drug-resistant forms of HIV-I International Antiviral News. 7: 89-97.  0.386
1999 Wainberg MA. Drug Therapy in HIV infection - Fourth International Congress Idrugs. 2: 18-19.  0.482
1999 Gotte M, Wainberg MA. Rescue of chain-terminated DNA synthesis: A novel concept to explain HIV resistance to zidovudine International Antiviral News. 7: 121.  0.415
1998 Wainberg MA. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase Antiviral Therapy. 3: 177-182. PMID 10682135  0.425
1998 Ungvarski PJ, Wainberg MA, Friedland G. Improving patient compliance with HIV treatment regimens (multiple letters) [3] Journal of the American Medical Association. 280: 1745-1746. PMID 9842947  0.373
1998 Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, Tsoukas CM. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons Aids. 12: 2125-2139. PMID 9833853 DOI: 10.1097/00002030-199816000-00007  0.543
1998 Friedman SR, Wainberg MA, Drucker E. Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications. Aids (London, England). 12: 2089-93. PMID 9833849 DOI: 10.1097/00002030-199816000-00003  0.399
1998 Cherry E, Liang C, Rong L, Quan Y, Inouye P, Li X, Morin N, Kotler M, Wainberg MA. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. Journal of Molecular Biology. 284: 43-56. PMID 9811541 DOI: 10.1006/Jmbi.1998.1968  0.684
1998 Caro C, Colby-Germinario S, Brenner B, Oliveira M, Wainberg MA, Germinario RJ. Sugar transport and glut transporter expression in a variety of human immunodeficiency virus-1 (HIV-1) chronically infected target cell lines. The International Journal of Biochemistry & Cell Biology. 30: 1031-8. PMID 9785466 DOI: 10.1016/S1357-2725(98)00061-2  0.412
1998 Rong L, Liang C, Hsu M, Kleiman L, Petitjean P, de Rocquigny H, Roques BP, Wainberg MA. Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA. Journal of Virology. 72: 9353-8. PMID 9765488 DOI: 10.1128/Jvi.72.11.9353-9358.1998  0.604
1998 Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Aids (London, England). 12: 1619-24. PMID 9764780 DOI: 10.1097/00002030-199813000-00008  0.399
1998 Drosopoulos WC, Rezende LF, Wainberg MA, Prasad VR. Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? Journal of Molecular Medicine (Berlin, Germany). 76: 604-12. PMID 9725762 DOI: 10.1007/S001090050257  0.608
1998 Quan Y, Inouye P, Liang C, Rong L, Götte M, Wainberg MA. Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing. The Journal of Biological Chemistry. 273: 21918-25. PMID 9705331 DOI: 10.1074/Jbc.273.34.21918  0.667
1998 Liang C, Rong L, Götte M, Li X, Quan Y, Kleiman L, Wainberg MA. Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription. The Journal of Biological Chemistry. 273: 21309-15. PMID 9694891 DOI: 10.1074/Jbc.273.33.21309  0.602
1998 Cherry E, Morin N, Wainberg MA. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication Aids. 12: 967-975. PMID 9662192 DOI: 10.1097/00002030-199809000-00003  0.531
1998 Liang C, Rong L, Laughrea M, Kleiman L, Wainberg MA. Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication. Journal of Virology. 72: 6629-36. PMID 9658109 DOI: 10.1128/Jvi.72.8.6629-6636.1998  0.684
1998 Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance Journal of the American Medical Association. 279: 1977-1983. PMID 9643862 DOI: 10.1001/Jama.279.24.1977  0.522
1998 Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1 Aids Research and Human Retroviruses. 14: 735-740. PMID 9643373 DOI: 10.1089/Aid.1998.14.735  0.562
1998 Libonatti O, Avila M, Zlatkes R, Pampuro S, Peralta LM, Rud E, Wainberg M, Salomón H. First report of HIV-2 infection in Argentina. Journal of Acquired Immune Deficiency Syndromes. 18: 190-191. PMID 9637587 DOI: 10.1097/00042560-199806010-00014  0.503
1998 Mayers D, Bethel J, Wainberg MA, Weislow O, Schnittman S. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (Codon 215) and didanosine (Codon 74) Journal of Infectious Diseases. 177: 1730-1733. PMID 9607859 DOI: 10.1086/517433  0.51
1998 DeLuca C, Kwon H, Pelletier N, Wainberg MA, Hiscott J. NF-kappaB protects HIV-1-infected myeloid cells from apoptosis. Virology. 244: 27-38. PMID 9581775 DOI: 10.1006/Viro.1998.9085  0.401
1998 Arts EJ, Quiñones-Mateu ME, Albright JL, Marois JP, Hough C, Gu Z, Wainberg MA. 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. Journal of Virology. 72: 4858-65. PMID 9573252 DOI: 10.1128/Jvi.72.6.4858-4865.1998  0.68
1998 Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, Fong IW, Schlech W, Djurdjev O, Freedman J, Thomas R, Lafrenière R, Wainberg MA, Cassol S, O'Shaughnessy M, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. Aids Research and Human Retroviruses. 14: 483-90. PMID 9566550 DOI: 10.1089/Aid.1998.14.483  0.534
1998 Huang Y, Khorchid A, Gabor J, Wang J, Li X, Darlix JL, Wainberg MA, Kleiman L. The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1. Journal of Virology. 72: 3907-15. PMID 9557676 DOI: 10.1128/Jvi.72.5.3907-3915.1998  0.487
1998 Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Jama. 279: 930-7. PMID 9544767 DOI: 10.1001/Jama.279.12.930  0.571
1998 Kwon H, Pelletier N, DeLuca C, Genin P, Cisternas S, Lin R, Wainberg MA, Hiscott J. Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. The Journal of Biological Chemistry. 273: 7431-40. PMID 9516441 DOI: 10.1074/Jbc.273.13.7431  0.511
1998 Quan Y, Gu Z, Li X, Liang C, Parniak MA, Wainberg MA. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. Journal of Molecular Biology. 277: 237-47. PMID 9514745 DOI: 10.1006/Jmbi.1997.1592  0.477
1998 Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, Wainberg MA. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Research. 25: 4532-6. PMID 9358162 DOI: 10.1093/Nar/25.22.4532  0.484
1998 Arts EJ, Quiñones-Mateu ME, Albright JL, Marois J, Hough C, Gu Z, Wainberg MA. 3′-Azido-3′-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants Journal of Virology. 72: 4858-4865. DOI: 10.1128/jvi.72.6.4858-4865.1998  0.643
1998 Huang Y, Khorchid A, Gabor J, Wang J, Li X, Darlix J, Wainberg MA, Kleiman L. The Role of Nucleocapsid and U5 Stem/A-Rich Loop Sequences in tRNA3Lys Genomic Placement and Initiation of Reverse Transcription in Human Immunodeficiency Virus Type 1 Journal of Virology. 72: 3907-3915. DOI: 10.1128/jvi.72.5.3907-3915.1998  0.39
1998 Acel A, Udashkin BE, Wainberg MA, Faust EA. Efficient Gap Repair Catalyzed In Vitro by an Intrinsic DNA Polymerase Activity of Human Immunodeficiency Virus Type 1 Integrase Journal of Virology. 72: 2062-2071. DOI: 10.1128/Jvi.72.3.2062-2071.1998  0.41
1998 Ehresmann C, Ehresmann B, Marquet R, Wainberg M. A sequence analysis of the primer binding site (PBS) region of the RNA genome of simian and human immunodeficiency viruses (SIV and HIV) Nucleic Acids Research. 26: 1134-1134. DOI: 10.1093/Nar/26.4.1134  0.474
1998 Wainberg MA, Cameron DW. HIV resistance to antiviral drugs: public health implications Drug Resistance Updates. 1: 104-108. DOI: 10.1016/S1368-7646(98)80025-3  0.489
1998 Wainberg MA, Montaner JSG. Emerging challenges in the clinical testing of new drugs for HIV disease International Antiviral News. 6: 224-226.  0.436
1997 Soudeyns H, Wainberg MA. Effects of RU486 on HIV-1 replication [2] Nature Medicine. 3: 1302-1303. PMID 9396582 DOI: 10.1038/Nm1297-1302B  0.548
1997 Liang C, Rong L, Morin N, Cherry E, Huang Y, Kleiman L, Wainberg MA. The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA. Journal of Virology. 71: 9075-86. PMID 9371564 DOI: 10.1128/Jvi.71.12.9075-9086.1997  0.664
1997 Bour S, Geleziunas R, Wainberg MA. Inhibition of CD4 translation mediated by human immunodeficiency virus type 1 envelope protein in a cell-free system. The Journal of Biological Chemistry. 272: 29005-14. PMID 9360974 DOI: 10.1074/Jbc.272.46.29005  0.389
1997 Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. Aids Research and Human Retroviruses. 13: 1403-9. PMID 9359660 DOI: 10.1089/aid.1997.13.1403  0.464
1997 Liang C, Li X, Quan Y, Laughrea M, Kleiman L, Hiscott J, Wainberg MA. Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription. Journal of Molecular Biology. 272: 167-77. PMID 9299345 DOI: 10.1006/Jmbi.1997.1239  0.489
1997 Li X, Liang C, Quan Y, Chandok R, Laughrea M, Parniak MA, Kleiman L, Wainberg MA. Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1. Journal of Virology. 71: 6003-10. PMID 9223491 DOI: 10.1128/Jvi.71.8.6003-6010.1997  0.476
1997 Liang C, Li X, Rong L, Inouye P, Quan Y, Kleiman L, Wainberg MA. The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. Journal of Virology. 71: 5750-7. PMID 9223461 DOI: 10.1128/Jvi.71.8.5750-5757.1997  0.69
1997 Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials Leukemia. 11: 85-88. PMID 9209307  0.528
1997 Li X, Quan Y, Wainberg MA. Controlling elements in replication of the human immunodeficiency virus type 1 Cellular and Molecular Biology (Noisy-Le-Grand, France). 43: 443-454. PMID 9193800  0.445
1997 Rübsamen-Waigmann H, Huguenel E, Paessens A, Kleim JP, Wainberg MA, Shah A. Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load. Lancet. 349: 1517. PMID 9167463 DOI: 10.1016/S0140-6736(97)24021-3  0.437
1997 Huang Y, Khorchid A, Wang J, Parniak MA, Darlix JL, Wainberg MA, Kleiman L. Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1. Journal of Virology. 71: 4378-84. PMID 9151827 DOI: 10.1128/Jvi.71.6.4378-4384.1997  0.425
1997 Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Journal of Virology. 71: 3023-30. PMID 9060662 DOI: 10.1128/Jvi.71.4.3023-3030.1997  0.582
1997 Mak J, Khorchid A, Cao Q, Huang Y, Lowy I, Parniak MA, Prasad VR, Wainberg MA, Kleiman L. Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. Journal of Molecular Biology. 265: 419-31. PMID 9034361 DOI: 10.1006/Jmbi.1996.0742  0.486
1997 Nagai K, Wong AH, Li S, Tam WN, Cuddihy AR, Sonenberg N, Mathews MB, Hiscott J, Wainberg MA, Koromilas AE. Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. Journal of Virology. 71: 1718-25. PMID 8995707 DOI: 10.1128/Jvi.71.2.1718-1725.1997  0.534
1997 Huang Y, Wang J, Shalom A, Li Z, Khorchid A, Wainberg MA, Kleiman L. Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1. Journal of Virology. 71: 726-8. PMID 8985405 DOI: 10.1128/Jvi.71.1.726-728.1997  0.413
1997 Foli A, Sogocio KM, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H, Yarchoan R. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antiviral Research. 32: 91-8. PMID 8891168 DOI: 10.1016/0166-3542(95)00985-X  0.603
1997 Huang Y, Khorchid A, Wang J, Parniak MA, Darlix JL, Wainberg MA, Kleiman L. Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1. Journal of Virology. 71: 4378-4384. DOI: 10.1128/jvi.71.6.4378-4384.1997  0.303
Show low-probability matches.